

# ANNUAL REPORT

## 2019



**TrueBeam** Linear Accelerator  
Latest Radiotherapy Machine



ডেল্টা হাসপাতাল লিমিটেড  
**Delta Hospital Limited**

# ANNUAL REPORT 2019

Financial Year 2018-2019



ডেল্টা হাসপাতাল লিমিটেড  
**Delta Hospital Limited**



### **Vision**

To be the leading multidisciplinary General and Specialized Cancer Hospital in the country with best services and highest social commitment.

### **Mission, Belief**

- 1) To provide world- class health care services at an affordable cost in General Medical Fields.
- 2) Diagnosis of Cancer and its prevention.
- 3) The treatment of cancer patients and Management at an affordable cost.
- 4) To be socially responsible and accountable to each of the constituents with whom we interact namely, our clients, employees, fellow citizens, business associates and our Shareholders.

### **Core Values**

Our Values: A guide to our decision making as we move to our future-

- Consistently excelling at patient-centered care.
- Acting with personal integrity and accountability.
- Respecting one another.
- Effecting change through teamwork and system thinking
- Supporting our diverse communities

### **Our Objectives**

Our objectives are to conduct transparent business operation based on market mechanism within the legal & social frame work with aims to attain the mission reflected by our vision.

# Contents

Corporate Information	02
Notice of 33 <sup>rd</sup> Annual General Meeting	03
Ten Principles of Global Compact (UN)	04
Ethical Principles	05
Message from Managing Director	07
Corporate Governance	09
Board of Directors	12
Committee Members	14
♦ Executive Committee	14
♦ Audit Committee	14
♦ Nomination & Remuneration Committee	15
♦ Operational Management Team	15
Directors Profile, Who seek re- appointment	16
Performance Indicator	18
Corporate Operational Results	19
Number of Meetings	19
Directors' Report to the Shareholders	20
Declaration by MD and CFO	31
Compliance Certificate	32
Status of Compliance of Corporate Governance	33
Photo Album	43
List of Doctors, Pathologists & Medical Physicists	45
Medical Services	55
Auditors' Report	56
♦ Statement of Financial Position	61
♦ Statement of Profit or Loss and other Comprehensive Income	62
♦ Statement of Changes in Equity	63
♦ Statement of Cash Flows	64
♦ Notes to the Financial Statements	65
Annexure of Property, Plant & Equipment	85
Form of Proxy	



## Corporate Information

Date of Incorporation	: June 4, 1987
Formal Inauguration	: May 1989
Total Employees	: 635
Number of Shareholders	: 230
Authorized Capital	: Tk. 1,000,000,000.00
Paid Up Capital	: Tk. 332,126,940.00
Registered office	: 26/2, Principal Abul Kashem Road Mirpur-1, Dhaka-1216 Phone: 9029152, 58050661, 58053461, 58050663, 9022410 Mobile: 01720238662 Fax: 880-2-9011372 E-mail: delta@delta-hospital.com Website: www.delta-hospital.com
Uttara Unit	: Plot-21, Sector-08, Abdullahpur, Uttara, Dhaka-1230. Mobile: 01787661376
Auditors	: FAMES & R Chartered Accountants
Principal Banker	: NCC Bank Limited Darus Salam Road Branch Mirpur-1, Dhaka

## **DELTA HOSPITAL LTD.**

26/2, Principal Abul Kashem Road, Mirpur-1, Dhaka-1216  
Phone: 9029152, 58053461, 58050661, 58050663, 9022410  
Mobile: 01720238662, Fax: 880-2-9011372  
E-mail: delta@delta-hospital.com, Web site: www.delta-hospital.com

### **NOTICE OF THE 33<sup>RD</sup> ANNUAL GENERAL MEETING**

Notice is hereby given that the 33<sup>rd</sup> Annual General Meeting of the Shareholders of Delta Hospital Ltd. will be held on Friday, 20<sup>th</sup> March, 2020 at 3.30 p.m. at Delta Hospital's Auditorium (9<sup>th</sup> Floor, Block-B) to transact the following business:

#### **AGENDA**

01. To receive, consider and adopt the Audited Financial Statements of the Company for the year ended June 30, 2019 together with reports of the Auditors and the Directors thereon.
02. To declare dividend for the year ended June 30, 2019.
03. To elect Directors in terms of the relevant provision of Articles of Association
04. To approve re-appointment of Managing Director and his remuneration.
05. To approve re-appointment of Independent Director
06. To appoint Auditors for the year 2019-2020 and to fix their remuneration.
07. To appoint Compliance Auditors for the year 2019-2020 and to fix their remuneration.

Dated: Dhaka  
March 4, 2020

By order of the Board



**Al- Mamun ACS**  
Company Secretary

#### **Notes:**

1. The Record date was 13<sup>th</sup> February 2020. The Shareholders whose names will appear in the Share Register of the Company on the Record Date will be eligible to attend the Annual General Meeting and receive the Dividend.
2. Members entitled to attend and vote at the Annual General Meeting may appoint a Proxy to attend and vote on his/her behalf. The proxy form must be affixed with requisite revenue stamp and must be deposited at the Registered Office of the Company not less than 48 hours before the time fixed for the Annual General Meeting.
3. Admission into the meeting venue will be allowed on production of the Attendance Slip attached with the Proxy Form.
4. Members are requested to update/confirm/provide particulars of their Bank Account, BO Account, change of address (if any) and 12 digit Taxpayer's Identification Number (E-TIN).



## The Ten Principles of Global Compact (UN)

The ten principles of Global Compact initiated by the UN Secretary General as have been adopted by Delta hospital Ltd. are as follows:

### Human Rights:

- 1) Business should support and respect the protection of internationally proclaimed human rights within their sphere of influence; and
- 2) Make sure that they are not complicit in human rights abuse.

### Labor Standards:

- 3) Businesses should uphold the freedom of association and the effective recognition of the right to collective bargaining;
- 4) The elimination of all forms of forced and compulsory labor;
- 5) The effective abolition of child labor, and
- 6) Eliminate discrimination in respect of employment and occupation.

### Environment:

- 7) Business should support a precautionary approach to environmental challenges;
- 8) Undertake initiatives to promote greater environmental responsibility; and
- 9) Encourage the development and diffusion of environment friendly technologies.

### Ethical Standards

- 10) Business should work against corruption in all its forms, including extortion and bribery.

### We Strive For:


- ◆ Top quality health care services at the least cost reaching the lowest rungs of the economic class of people in the country.
- ◆ The protection of Shareholders' capital as well as ensuring highest return and growth of their assets.
- ◆ The best compensation's to all the employees who constitute the back-bone of the management and operational strength of the Company through a pay-package composing salary/wages, allowances, bonus and retirement benefits.
- ◆ The best Co-operation of the creditors and debtors, the banks and financial institutions who provide financial support when we need them, the suppliers of medicine & other items who offer them at the best prices at the opportune moments and providers of utility services-power, gas & water etc.
- ◆ The fulfillment of our responsibility to the Government through payment of entire range of due taxes, duties and claims by various public agencies like municipalities, etc.
- ◆ Achieving a social order devoid of malpractices, anti-environmental and anti-social behaviors, unethical and immoral activities and corruptive dealings.
- ◆ Practicing good- governance in every sphere of activities covering inter alia not being limited to, disclosure & reporting to shareholder, holding AGM in time, recruitment & promotion of staff, procurements & supplies, sale of assets etc. all that directly and indirectly affect the interest of concerned group- the Shareholders, the Creditors, Suppliers, Employees, Government and the public in General.
- ◆ Equality between sexes, races, religions and regions in all spheres of our operation without any discriminatory treatment.
- ◆ Creating an environment free from pollution and poisoning.
- ◆ The achievement of millennium Development goals for the Human Civilization.
- ◆ The national development and prosperity.

## Ethical Principles

Ethical Principles is based on our corporate values and it expresses basic ethical code, attitudes and rules that the Company's Employees follow at their work. We always have a firm and clearly defined corporate culture. It is the way we talk to each other, cooperate, create, behave in certain circumstances and at the same time it expresses what is important for us.

	Fairness	Transparency	Respect
Colleagues	<ul style="list-style-type: none"> <li>▶ Ban discrimination on the ground of sex, race and political opinion;</li> <li>▶ Practice respect and care towards employees at all time;</li> <li>▶ Ban favoritism in recruitment, promotion, training and incentive policies</li> </ul>	<ul style="list-style-type: none"> <li>▶ Share your knowledge without monopolizing it to your own advantage;</li> <li>▶ Ensure transparency in career path.</li> </ul>	<ul style="list-style-type: none"> <li>▶ Clearly define duties and responsibilities for all employees;</li> <li>▶ Listen and pay constant attention to employees, respecting their values, feeling, and moral stance; never use any form of undue pressure or offense.</li> </ul>
Clients	<ul style="list-style-type: none"> <li>▶ Strive for client satisfaction at all times;</li> <li>▶ Pay appropriate attention to each of our clients</li> </ul>	<ul style="list-style-type: none"> <li>▶ Ensure timely information on products and services at all times.</li> </ul>	<ul style="list-style-type: none"> <li>▶ Maintain confidentiality of any information acquired, both in relation to clients and the company itself and its decisions; safeguard its assets.</li> </ul>
Investors	<ul style="list-style-type: none"> <li>▶ Pay appropriate attention to the investors, without discrimination or favoritism.</li> </ul>	<ul style="list-style-type: none"> <li>▶ Aim to be clear, complete and timely;</li> <li>▶ Use most effective communication channel for investors;</li> <li>▶ Turn market communication into an economic and cultural value.</li> </ul>	<ul style="list-style-type: none"> <li>▶ Behave with investors in line with corporate values and professional ethics as required by market's highest standards.</li> </ul>
Communities	<ul style="list-style-type: none"> <li>▶ Establish suitable relations with stakeholders in order to offer assistance, service and opportunities without discrimination.</li> </ul>	<ul style="list-style-type: none"> <li>▶ Keep the community we work informed of what we do and how we do it.</li> </ul>	<ul style="list-style-type: none"> <li>▶ Promote growth which is ecologically and socially sustainable.</li> </ul>

	Reciprocity	Freedom	Trust
Colleagues	<ul style="list-style-type: none"> <li>▶ Trying to have a positive influence in our working environment'</li> <li>▶ Co-operate, Sharing knowledge to generate value and find legitimating of our professional identity beyond organizational boundaries;</li> <li>▶ Taking care of colleagues' needs.</li> </ul>	<ul style="list-style-type: none"> <li>▶ Create proper environment, freedom of dissent and freedom to express what one thinks;</li> <li>▶ Offer everybody the chance to practice the values of leadership and develop his/her own professional personality.</li> </ul>	<ul style="list-style-type: none"> <li>▶ Keep our commitment, admitting the possibility of mistakes made in good faith.</li> </ul>
Clients	<ul style="list-style-type: none"> <li>▶ Offer a good return and a feeling of certainty to clients, to receive the equivalent in return;</li> <li>▶ Listen to requirements and transform them into products and services.</li> </ul>	<ul style="list-style-type: none"> <li>▶ Handle interpersonal relations in free and equal terms without being in awe of those who are stronger and without arrogance towards those who are weaker.</li> </ul>	<ul style="list-style-type: none"> <li>▶ Build-up confidence through behaviors that constantly confirm our reputation.</li> </ul>
Investors	<ul style="list-style-type: none"> <li>▶ Listen without prejudice to any indications that investors may communicate.</li> </ul>	<ul style="list-style-type: none"> <li>▶ Achieve freedom of action such that we can keep the promises we make to the market without undue conditioning.</li> </ul>	<ul style="list-style-type: none"> <li>▶ Develop lasting and continuous relationship with the financial community;</li> <li>▶ Safeguard our consistency and credibility;</li> <li>▶ Willingly accept any criticism expressed by the market.</li> </ul>
Communities	<ul style="list-style-type: none"> <li>▶ Create spaces for discussion and dialogue in which mutual exchange of information may increase our legitimacy and reputation.</li> </ul>	<ul style="list-style-type: none"> <li>▶ Respect individual moral codes and culture.</li> </ul>	<ul style="list-style-type: none"> <li>▶ Establish social and cultural relations with communities, whose distinctive features should be reciprocity.</li> </ul>



## Message

Managing Director  
Delta Hospital Limited

### Dear Shareholders,

We are pleased to inform you that we have ended yet another successful year with satisfactory results. Despite the increasingly challenging environment, we continue to grow our business profitably. This would not have been possible without our people. Delta Hospital Limited, our members are passionate about making a measurable impact in everything we do. It is the power of our people, our unique culture and innovative approach, which helps us deliver enduring results.

Progress, for me has never been a dream. It has always been a distant reality and once one milestone is achieved, there is always another one waiting to be crossed. It is with this belief that we started Delta Hospital Ltd. in 1987. We always wanted to push my company to more milestones that are prosperous.

Delta Hospital Limited has made significant investments in expanding its area of services that allow smooth functioning of its operational process. The company has also delinquently recruited renowned Doctors, technical persons and professional workforce that well complements its strides towards growth.

### Review of Financial Performance

The company's revenue has increased by Tk. 6.10 crore, an increment of 10.31% compared to previous year. The revenue was Tk. 65.33 crore in the year 2018-19. The company has achieved a Gross Profit Margin of 39.18%. The Net Profit after tax for the reporting year is 6.99 crore. Corporate tax of 35% that was applicable to the Hospital sector. Last year company achieved a Net Profit after tax of Tk. 6.89 crore. Accordingly, Earnings Per Share (EPS) this year has Tk. 2.10 and previous year's Earnings Per Share of Tk. 2.08.



**Turnover**

The Company achieved operating turnover of Tk. 65.33 crore recording a 10.31% growth. Growth in all business lines of the company including radiotherapy services, chemotherapy, laboratory investigations, operation theatre services, radiology and diagnostics services contributed to the revenue. The radiotherapy, chemotherapy, laboratory investigations, operation theatre and others is one of the most successful units in our hospital. As a result of the constant improvements to this unit.

**Expenses**

Staff costs increased by 22% during the year to Tk. 19.03 crore from Tk. 15.66 crore in the previous year. This was due to the salary revisions made at the beginning of the period. Administration expenses increased by 13%, over the previous year expense of Tk. 10.79 crore and currently stands at Tk. 12.15 crore. During the year, operating expenses increased to Tk. 39.73 crore, Last year operating expenses were Tk. 35.10 crore and it has increased by 13.19% in the current year. During the year, net financial costs increased by 37.29% to Tk. 4.80 crore from Tk. 3.49 crore recorded in the previous year.

**Review of financial position****Assets base**

Total assets base of the company increased by 12.50% compared to the previous year's asset of Tk. 258.88 crore and currently stands at Tk. 291.25 crore. Out of this Tk. 32.37 crore increments, Tk. 17.20 crore is due to the net changes in Property Plant and Equipment.

Healthcare worldwide is becoming more and more expensive, but we try to make our services affordable. Healthcare, though deemed as an 'industry' is much more than that – we strongly believe that profit should be a byproduct and not the aim in healthcare, which helps us to transcend into our core values, of Compassion, Integrity and Respect. In an exercise to serve all sections of the society, we have rolled out different brands with varying price bands. We also provide support to those who are in need through our poor fund as CSR activities.

In conclusion, I would like to extend my appreciation to our team of highly skilled employees, the Board of Directors, consultants, and the Management who contributed to making this year exceptional for Delta. I would also like to thank our customers for their continued trust, and our shareholders, and business partners for placing their confidence in our establishment.

With warm regards,



**Dr. Syed Mukarram Ali**

Managing Director

Delta Hospital Limited

## Corporate Governance

Corporate Governance involves decision making process for any corporate body as a going concern for the benefit of all concerned, present and future. These decisions may be categorized as policy and strategic, operational and executing, performance and evaluation and sharing of the accretion assets between present and future cohorts. The involvement of the entrepreneur in all these areas invokes decision-making process on a continuous basis, the degree of involvement being variable with the extent of delegation of authority top down and reporting for accountability bottom up of the Management echelon. These aspects of governance are shared by the Board of Directors, Executive Committee, operational participants and others in the fulfillment of common goals that coverage in increasing the benefits of all stakeholders. To this end entire corporate governance efforts are blended with good governance practices as ethically and morally acceptable standards under a given socio-politico- environmental phenomenon of our society in which we work, live and exist.

The organs through which the corporate governance functions are carried out are:

### BOARD OF DIRECTORS

#### (a) Constitution:

The Board is headed by the Chairman. The Board of Directors, the top policy making echelon, consisting of the founding entrepreneurs/ successors provides the policy and strategic support directions for the entire range of the corporate activities. The Board of Directors are varied education and experience, which provides a balancing character in decision- making process. The Board is re-constituted every year at the Annual General Meeting when one-third of the members retires and seeks re-election. A director is liable to be removed, if the conditions of the Articles of Association and the provisions of the Companies Act 1994 are not fulfilled.

#### (b) Role & Responsibilities:

The main role of the Board of Directors which is the highest level of authority is to provide general superintendence, oversee the operations and control the affairs of the company through appropriate delegation and accountability processes via the lines of command. The Board of Directors hold the ultimate authority, responsibility and accountability with due diligence for conducting the activities of the company as per the provisions of law in the interest of the shareholders, the stakeholders, the state and the society. The Board of Directors, in the fulfillment of its responsibility, holds periodic meetings, at least once in every two months and provides appropriate decisions/ directors to the Executive Committee. Such meetings usually consider operational performance, financial results, and review of budgets, capital expenditure proposals of BMRE (Balancing, Modernization, Rehabilitation and Expansion) or new projects/ divisions/ service lines, procurement of funds by issue of shares or borrowing, procurement of Plant & Machinery, Pricing of Services/ Discounts, Recruitment, Training and Promotion of Officers, Approval of Audited Accounts and Distribution of Dividends and other interests of the stakeholders including the employees. The Board of Directors takes special care in designing and articulating productivity and compensation plans of employees and workers and rewarding them appropriately on the basis of quality and quantity of performance as an incentive. Board also remains responsible for the removal of operational hazards to life and health of employees, friendly environmental work condition and social relationship as demanded of good citizen in a country.

#### (c) Relationship with Shareholders & Public:

The shareholders, as owners, are required to be provided with material information on the Company's operation annually, the latter at the AGM.

They are also provided with routine services by the Company Secretary in matters of transfer of shares, payment of dividends etc. A qualified Secretary is in charge of all these responsibilities as Company Secretary.

#### **(d) Relationship with Government:**

In its role on accountability to the government the Board of Directors ensure payment of all dues to government in the form of import duty, custom duty and port charges, VAT, Corporate Taxes and other levies as and when they become due on the basis of actual operations and make sure to avoid corruption. This has enabled the Company to enhance its contribution to the National Exchequer on a progressive rate year after year.

#### **(e) Relationship with Finance/Bankers:**

The board oversees the financial transactions and ensures to meet Company's Commitments to the lenders without default. This has resulted in securing lower interest rates from them.

#### **(f) Relationship with Suppliers:**

As the Company has to import plant and machinery from abroad, it maintains cordial and mutually beneficial interest with its international as well as local suppliers. This has enabled the Company to avoid any legal disputes in international/local courts and enhanced the Company's Image as a good customer.

#### **(g) Corporate Social Responsibilities (CSR):**

The Board of directors is also aware of the Corporate Social Responsibility (CSR) especially in the areas of gender equality, race-religion- regional equality, non- employment of child labor, human rights, and environmental pollution, social-marketing, social activities (Promotion of Sports and Cultures, Healthcare and Population Control Programs, Eliminations of corruption programs, participation in charitable activities like Free Medical Camp and Free Consultation and Medicine etc. in non-partisan manner) right to form and participate in Union under ILO convention, employment of disables etc.

#### **Nomination and Remuneration Policy**

At all levels and all times monetary compensation has been if not the sole but the most important motivational aspect for getting the job fulfilled under any given business scenario.

It is the endeavor of Delta Hospital Limited (Company) that its Nomination & Remuneration Policy should represent the mode in which the Company carries out its business practices i.e. fair, transparent, inclusive and flexible.

The Company strives that its Remuneration Policy should attract, motivate, improve productivity and retain manpower, by creating a congenial work environment, encouraging initiatives, personal growth and team work, and inculcating a sense of belonging and involvement, besides offering appropriate remuneration packages and superannuation benefits.

This Nomination and Remuneration Policy applies to Directors, Key Managerial Personnel (KMP), Senior Management and other employees of the Company.

In pursuance of the Company's policy to consider human resources as its invaluable assets, to pay equitable remuneration to all Directors, Key Managerial Personnel and Employees of the company, to harmonize the aspirations of human resources consistent with the goals of the company. This policy on nomination and remuneration of Directors, Key Managerial Personnel (KMP) and Senior Management has been formulated by the Nomination and Remuneration Committee ("NRC") and approved by the Board of Directors of the Company.

The evaluation criteria and activities of NRC during the year:

The Remuneration and Nomination Committee, in accordance with its regulations, meets whenever it is convened by the Board of Directors, the Committee itself, or by its Chairman. The Committee shall meet at least one (1) time per annum and at such other times as it sees fit. During the fiscal year 2018-2019 the Remuneration and Nomination Committee has met one time.

Only members of the Committee have the right to attend Committee meetings. However, other individuals such as the Chief Financial Officer, the General Manager Human Resources & Admin, Hospital Director and others may be invited to attend for all or part of meeting, as and when appropriate and necessary.

The Company Secretary keeps Minutes of all Remuneration and Nomination Committee meetings, which are available to all members of the Board of Directors.

The main tasks carried out by the Committee during the fiscal year 2018- 19 have been the following:

- A new performance share plan (the "New PSP")
- Director Remuneration Policy
- Director Selection Policy
- Salary increase proposal and the human resources remuneration taskforce.
- A new long Term Incentive Policy ("LTIP 2018-19").
- The performance conditions in relation to this LTIP
- The executive Board members allocation under the LTIP 2018-19.
- Proposal on renewal of independent Directors and proprietary Director

#### **Executive Committee (EC):**

The Executive Committee (EC) is led by the Chairman who is appointed by the Board of Directors. The Executive Committee (EC) consists of Six (06) members including Chairman with varied education and experiences, which provides a balancing character in decision-making process. The main responsibility of the EC is to oversee the business operation, solve the emergency need, and procure Plant, Machinery etc. The EC is responsible to the Board. The decision of the EC are to be ratified by the Board of Directors.

#### **Audit Committee:**

The Audit Committee consists of Six (06) members including Chairman with varied education and experiences, which assists the Board of Directors in ensuring that the financial statements reflect a true and fair view of the state of affairs of the company. The member of the Audit Committee, in fulfillment of its responsibility, holds periodic meetings, one meeting in every three months. The main responsibility of the Audit Committee is to oversee the financial reporting process, monitor choice of accounting policies and principles, internal control risk management process, Review the adequacy of internal audit functions, etc. The Audit Committee is responsible to the Board of Directors. The minutes of the Audit Committee are to be approved by the Board of Directors

#### **Nomination and Remuneration Committee**

The Board of Directors of the Company (the Board) has constituted the Nomination and Remuneration Committee (NRC) as a subcommittee of Board. The committee consists of Four (4) non-executive directors out of which one is independent director. The Chairman of the Committee is an Independent Director. The NRC shall conduct at least one meeting in a financial year.

#### **Other Governance Apparatus:**

The Company, in its efforts of Corporate Good Governance Practices, uses a series of top ranking professional service providers including legal experts, bankers, insurers and technical experts who continuously assist the Board of Directors and the Executive Committee in properly discharging their duties and responsibilities to all the shareholders, stakeholders, the Government and the public.



## Board of Directors



Mr. Abu Saleh Abdul Muiz  
Chairman




Dr. Syed Mukarram Ali  
Director & Managing Director



Engr. Mir Amjad Hussain  
Director



Mr. Habibur Rahman  
Director




Mrs. Nazmin Showkat Ali  
Director



Mr. Mohd. Shawkat Ali  
Director



Mr. Nurul Huda  
Director



Mr. Mahmud Hassan  
Director

## Board of Directors



Mr. Obiydur Rahman  
Director



Mr. Mizanur Rahman Sarker  
Director



Mr. Kamran Idris Choudhury, FCA  
Independent Director



Dr. Shamim Jahangir Ahmed  
Independent Director



Dr. Chowdhury Habibur Rahman, FRCS  
Independent Director

## Committee Members

### Executive Committee

Mr. Abu Saleh Abdul Muiz	Chairman
Dr. Syed Mukarram Ali	Member
Engr. Mir Amjad Hussain	Member
Mr. Nurul Huda	Member
Mr. Obiydur Rahman	Member
Dr. Chowdhury Habibur Rahman, FRCS	Member

### Audit Committee

Mr. Kamran Idris Choudhury, FCA	Chairman
Dr. Syed Mukarram Ali	Member
Mr. Habibur Rahman	Member
Mrs. Nazmin Showkat Ali	Member
Mr. Mizanur Rahman Sarker	Member
Dr. Shamim Jahangir Ahmed	Member

## Committee Members

### Nomination & Remuneration Committee

Mr. Kamran Idris Choudhury, FCA	Chairman
Dr. Syed Mukarram Ali	Member
Engr. Mir Amjad Hussain	Member
Mr. Abu Saleh Abdul Muiz	Member
Mr. Al-Mamun, ACS	Member Secretary

### Operational Management Team

Dr. Syed Mukarram Ali	Managing Director & Chief Consultant Pathologist
Dr. Parvin Akhter Banu	Chief Consultant, Department of Oncology
Prof. Dr. Kazi Manzur Kader	Senior Consultant & Head, Department of Oncology
Mr. Md. Bakbul Islam, FCMA	Chief Financial Officer
Dr. A.F.M Badruzzaman	Hospital Director
Mr. Md. Ali Ahad	General Manager, Administration
Mr. S. M. Enamul Kabir	Principal Medical Physicist & Coordinator, Dept. of Medical Physics
Mr. Al-Mamun, ACS	Company Secretary



## Directors Profile

### Who seek re- appointment

---

#### Dr. Syed Mukarram Ali



Dr. Syed Mukarram Ali founder Managing Director and past Chairman of Delta Hospital Limited was a professor of Pathology and did his M.B.B.S from University of Dhaka, M.Phil from University of Karachi, DCP from University of London. Completed FRC-Path. from Royal College of Pathologists, London and D.Path. from Royal College of Physicians & Surgeons, London. He is an honorary fellow of Bangladesh College of Physicians & Surgeons. Dr. S.M Ali had worked in Bangladesh, UK, and Kuwait during his long and illustrious medical career. He is an active member of International Academy of Pathology (Brit. Division) & Association of Clinical Pathology (UK), and a former president of Bangladesh Society of Pathologists. He is life member of Bangladesh Cancer society, Bangladesh Medical Association (BMA) and pathology society of Bangladesh. He was a Sponsor Director & former Chairman of Delta Life Insurance Company Limited. He had been the director of Delta BRAC Housing Limited (DBH) since its inception and former Vice Chairman of Green Delta Insurance Company Limited. He is the Chairman of board of trustee of Delta Medical College & Chairman of Globex Pharmaceuticals Limited. He was past President of Rotary Club of Dhanmondi, Dhaka, Ex EC member of Bangladesh Association of Publicly Listed Company (BAPLC) and The Federation of Bangladesh Chambers of Commerce and Industry (FBCCI).

---

#### Mr. Mir Amjad Hussain



Mr. Mir Amjad Hussain did his B.Sc. Engr. (Civil) from Bangladesh University of Engineering and Technology (BUET) in 1966. Mr. Hussain is a Fellow of Institute of Engineers Bangladesh and Member of Kuwait Society of Engineers. Mr. Hussain had worked with the government of Bangladesh, Iraq, and Kuwait during his long and distinguished Engineering career. He was Managing Director of Globex Pharmaceuticals Limited and Chairman of Delta Hospital Limited. Currently he is Managing Director of Shalbon Agro Private Limited.

## Directors Profile

### Who seek re- appointment

---

#### Mr. Habibur Rahman



Mr. Habibur Rahman is a business person by profession. He is a Director of Pubali Bank Ltd. He is also director of Pubali Bank Securities Limited and Globex Pharmaceuticals Limited. He is a dynamic entrepreneur of the country and had great contribution to formation of Delta Hospital Limited.

---

#### Mr. Nurul Huda



Mr. Nurul Huda did his M. Com (Management) from Dhaka University in 1982. He was former Director of Delta Life Insurance Company Limited, Vice Chairman & Director of Green Delta Insurance Company Limited and Director of Delta Brac Housing Finance Corporation Ltd. (DBH). He is presently Director of Delta Hospital Limited and Globex Pharmaceuticals Limited. He is also trustee member of Delta Medical College trust.

## Independent Director's Profile

### Who seek re- appointment

---


#### Mr. Kamran Idris Chowdhury FCA




Mr. Kamran Idris Chowdhury qualified in London as Chartered Accountant in 1981. He is a fellow of the Institute of Chartered Accountants (FCA), England and Wales (ICAEW) and Institute of Chartered Accountants of Bangladesh (ICAB). He worked for Touche Ross and Co (currently Deloitte Touche Tohmatsu) in London prior to returning to Bangladesh in 1988 and joined A. Qasem & Co, Chartered Accountants, the member firm of Ernst and Young in Bangladesh. He was partner in A. Qasem & Co from 1992 up until December 2014 when he retired from the partnership. He led major Audit and MCS assignments with multinational, overseas and joint venture companies, financial institutions and international donor agencies. Major clients included DFID, USAID, CARE and several foreign missions. He is on the Board of Directors of Green Delta Insurance Company Limited where he is currently holding the position of Vice Chairman.

## Performance Indicator


Turnover (Taka in million)



Net Profit After Tax (Taka in million)



Fixed Assets (Taka in million)



## Five (5) Years Financial Statistics

Particulars	2018-2019	2017-2018	2016-2017	2015-2016	2014-2015
Turnover	653,300,110	592,242,162	558,798,277	489,741,226	426,818,334
Net Profit Before Tax	94,829,772	108,409,633	107,008,012	97,614,327	69,939,495
Net Profit/(loss) after Tax	69,904,158	68,999,833	67,928,523	61,771,524	43,645,244
share capital	332,126,940	332,126,940	332,126,940	332,126,940	315,000,000
Total Assets	2,912,500,651	2,588,834,962	2,346,807,839	2,138,909,896	1,796,801,008
Long-Term borrowings	754,554,735	559,311,976	470,651,193	338,438,884	134,212,965
Total current Assets	266,930,844	397,963,496	320,487,897	260,989,965	178,908,606
Total current liabilities	476,811,110	393,178,715	281,673,627	249,890,554	194,041,096
Shareholders' Equity	1,522,595,928	1,491,935,170	1,462,137,682	1,328,539,113	1,257,855,301
Earnings Per Share(EPS)	2.10	2.08	2.05	1.88	1.39
NAV Per Share	45.84	44.92	44.02	40.00	39.93
No. Of Share Outstanding	33,212,694	33,212,694	33,212,694	33,212,694	31,500,000
Value Per share (TAKA)	10	10	10	10	10
No. of Shareholders	230	230	230	229	225

## Number of Meetings

Financial Year-2017-2018

Particulars	No. of Meeting held during the year
Board of Directors Meeting	07
Executive Committee (EC) Meeting	04
Audit Committee Meeting	04
Nomination & Remuneration Committee Meeting	01

## Directors' Report to the Shareholders for the year 2018-2019

### Dear Fellow Shareholders,

On behalf of the members of the Board of Directors of your company and on my own behalf, I welcome you all in the 33<sup>rd</sup> Annual General Meeting of Delta Hospital Limited. We, members of the Board are pleased to present Directors' Report, Audited Financial Statements for the year ended 30<sup>th</sup> June 2019 and Auditors' Report thereon before you for your consideration and approval.

### Financial Performance/Business Activities/ Expansion Program

The operating financial results of Company for year 2018-2019 and 2017-2018 are summarized hereunder :

Particulars	2018-2019 (Taka)	2017-2018 (Taka)	(%) Increase/(Decrease)
Total Revenue	666,492,185	607,813,989	9.65%
Gross Profit	255,981,583	241,226,923	6.11%
Net Profit After Tax	69,904,158	68,999,833	1.31%
Earnings Per Share	2.10	2.08	0.96%

### Dear Shareholders

#### Revenue

Though the company has confronted with many challenges and competitiveness in this year, we are still able to earn upward growth of revenue through our effort and innovation in services, which represents 9.65% increases in revenue. This revenue of Tk. 66.64 Crore in this year that is Tk. 5.86 Crore higher than previous year.

#### Gross Profit

The company has maintained its sustainable continuous profitability in this year with Gross Profit margin of Tk. 25.60 crore that is Tk. 1.47 crore higher than previous year of 2017-18, which is 6.11% increase in profit.

#### Net Profit after tax

Since the Company has control over cost efficiently and focus on revenue maximization that resulted overall increased in net profit after tax. In this year, the net profit after tax is Tk. 6.99 crore that is Tk. 0.90 crore higher than previous year. Though the operational and other expense has increased significantly, which is 13.04% still we are able to reach the growth of 1.31% in this year.

#### Earnings per Share (EPS)

In this year, the EPS of the company is Tk. 2.10 per share, which was Tk. 2.08 in the previous year. That means EPS has increased by Tk. 0.02 per share with the growth of 0.96%

You may review the Auditors Report for more details, which is appended to this report.

## Initial Public Offer (IPO)

### Dear Shareholders,

We are pleased to inform you that after long waiting Bangladesh Securities and Exchange Commission (BSEC) has allowed Delta Hospital Limited to determine its Cut-off price through eligible investors' bidding - a requirement for going public under the book building method. The Delta Hospital Limited will float IPO (initial public offering) shares under the book building method to raise a capital worth Tk.50.00 crore. Under the revised book-building method, eligible investors' are allowed to purchase 50% shares at the cut-off price and general public & non-resident Bangladeshis are allowed to purchase 40% and 10% shares respectively at 10% discount on the cut-off price. The Delta Hospital Limited will utilize the IPO proceeds as follows:

Sl. no.	Particulars	Quantity	Unit price (estimated)	Total Amount (Tk.)
01	To purchase Cobalt-60 machine (Radiotherapy machine)	1(One)	11,81,27,942.00	11,81,27,942.00
02	To purchase MRI machine	1(One)	11,01,08,049.00	11,01,08,049.00
03	To purchase CT Simulator machine	1(One)	7,23,12,537.00	7,23,12,537.00
04	To purchase Digital X-Ray machine	1(One)	82,00,000.00	82,00,000.00
05	To setup Bone marrow transplantation center		8,01,41,200.00	8,01,41,200.00
06	To repay bank loans		8,86,10,272.00	8,86,10,272.00
07	To bear the IPO expenses		2,25,00,000.00	2,25,00,000.00
	Total			50,00,00,000.00

We hope the process will be completed within this year depends on the capital market situation and approval of the Security Regulator.

### Progress of Expansion Project:

#### Construction of Building:

We are pleased to inform you that the 10 storied hospital building almost complete. Work on front boundary, gate & canopy and tiles works is in progress. We are expecting to complete the works within the end of March 2020. Hospital activities have been started such as patient's admission, Operation theatre, Neonatal Intensive Care Unit (NICU) etc.

#### Risk and Concern:

Investment in ordinary shares is fraught with various levels of risk. Consequently, the return of the investment is dependent on the functioning of the risk factors. Delta Hospital Limited operates in an industry, which is exposed to a number of internal and external risk factors over which the Company has little or no control. The occurrence of the risk factors as delineated hereunder, and if the management fails to avoid or mitigate those, can have significant bearing on the operational and financial performance of the Company, which, in turn, may negatively impact on the value of share of the Company. Therefore, it is imperative to thoroughly understand the risk profile of the Company along with management's perception of the risks for taking an informed investment decision.

**Credit risk:**

Credit risk on financial instruments is the risk of financial loss occurring as a result of default or insolvency of counterparty on its obligations to repay to the Hospitals, and arises principally from the receivable from customers and other parties.

**Management perception**

The Company pays its financial obligations from its operational income. Since its inception the revenue record of accomplishment, it is satisfactory to repay its debt obligation. So the Company shall not expose to credit risk in future.

**Liquidity risk;**

Liquidity is the ability of a company to pay its debts without suffering catastrophic losses. Liquidity risk is the risk that a company may be unable to meet short term financial demands.

**Management perception**

The Company has been generating sufficient revenue from its current business operation. In case of any emergency, the Company shall be availed fund or working capital to meet up any urgency from the existing lender. Again the Company has planned to raise fund through IPO to meet up capital requirement for the expansion project subject to approval of regulatory authority. The capital structure shall be diversified through equity financing and debt obligation shall be reduced accordingly through IPO. Again the Company has set out plan to repay existing debt obligation from IPO proceeds which will have positive impact on future profitability and cash management.

It is mentionable here that the operating cash flow of the Company is in positive trend. It express that the management capacity to maintain sufficient liquidity position in the Company.

**Insurance coverage not adequately protect against certain risks of damages:**

The Company would be exposed to significant loss if there are no insurance coverage on its assets.

**Management perception**

Delta Hospital Limited has sufficient insurance coverage to cash in safe, cash in transit and building and all major machineries are covered under fire insurance policy by Green Delta Insurance Company Limited to protect against certain risks of damages.

**Competitions:**

Competition refers to the risk of decreasing present market share caused by new entrants which could have an adverse impact on the business and result of operation.

**Management perception**

Management is aware about the competition and optimistic about future growth of the business.

**Interest rate risks;**

Interest rate risk is the chance that an unexpected change in interest rates will negatively affect the value of an investment as well as borrowing long term and short-term loan. Interest rate risk is mostly associated with fixed-income assets.

**Management perception**

The Company management is well aware of bank interest structure and always tries with best efforts for negotiating with lenders for reducing interest rate considering the prevailing market condition. The debt service coverage ratio is reflecting that the Company has ability to repay debt installment with interest. The Company emphasizes now on equity-based financing which will reduce interest rate risk



**Exchange rate risks;**

Foreign currency exposure arises from purchases and other transactions, which denominated in foreign currencies. The Company imports medical equipment and accessories time to time from foreign countries in foreign currency through Letter of Credit (LC). If any foreign currency exchange rate fluctuation happen during the period of LC opening and delivery at site, that may affect cash flow of the Company.

**Management perception**

The Company is fully aware of the risks related to currency fluctuation and minimizes exchange rate fluctuation risk by monitoring foreign exchange price movement on regular basis. In case of import of machinery, the company has to pay in foreign currency. The gain or loss in case of foreign currency rate fluctuation would not affect the company due to import volume is low.

**Industry risks;**

The Company is operating business in health service sector with specialization in cancer treatment. The growth of industry may hamper due to demand for cancer treatment significantly reduce or any other factors such as price fluctuation, scarcity of specialized doctor, competitors threat and unavailability of specialized machineries related with cancer treatment.

**Management perception**

The Company operates in health service sector providing general medical treatment especially in cancer treatment. Now a days cancer patient is increasing throughout the world as well as in Bangladesh. The Cancer treatment facility is limited in our country as few specialized hospitals are providing this type of services. So its presume that the industry may not fall in near future as the demand is increasing day by day.

**Technology related risks;**

Technology always plays a vital role for the existence of any business concern. A new technology may cause technological obsolescence and impact profitability.

**Management perception**

The Company has established to serve all cancer patients, rich and poor with an advanced technology. Therefore, in time, treatment quality will be at par with any other country so that patients may not need to travel outside Bangladesh. The oncology division is equipped with Doctors, skilled planners, technologist and nurses to work as a team to serve the patients. Our hospital is enriched with advanced machine (LINAC) for conformal radio therapy, Mammography, Simulators, CT-Scanners, X-ray Unit, Cobalt 60 tele- therapy Units and above all HDR unit (High Dose Rate Brachytherapy) for Cervical and Interluminal just to name a few.

Delta Hospital already includes facilities like Intensity Modulated Radiation Therapy (IMRT) including Image Guided Radiotherapy (IGRT) and Rapid Arc with state of the art technology in cancer therapy. The Company is equipped with most modern machineries and procuring them time to time as any up gradation is needed.

**Potential or existing government regulations;**

Delta Hospital Ltd operate primarily under Companies Act, 1994 and other related policies , rules and regulations, such as Health Policy, Income Tax Ordinance 1984, Value Added Tax (VAT) Act 1991, Customs Act, Bangladesh Environmental Conservation ACT, 1995. Any abrupt changes in the policy may adversely affect the business of the Company.

**Management perception**

Hospital Industry in Bangladesh is an emerging sector with considerable local demand. Considering the demand, it is expected that the government has been extended its policy support to smooth functioning of this sector. Current government regulations and policies are favorable to the business operation of the Company.

**Industry outlook and possible future developments in the industry:**

Health care industry is one of the most important sectors of the economy, since health services is a basic need for living and has strong stable demand. Bangladesh has achieved remarkable progress in the health care sector. The country experienced establishment of hundreds of hospitals and clinics in the private sector in the recent past because income of the people of Bangladesh started increasing along with their increasing purchasing capacity. The private sector started setting up their facilities across the country with affordable prices. Despite a very fast growing private sector the country has a shortage of skilled health care providers for which many middle class Bangladeshi patients travel to neighboring countries for better treatment which drains out our foreign exchange. In the financial year 2018-2019 the GDP growth rate was 8.13% which was 7.86% in the financial year 2017-2018. As the GDP is increasing gradually, peoples' health care spending is also likely to increase. On the other hand population is also increasing which will further increase the demand of health care. Moreover, treatment advancement and government initiatives to increase medical services access will drive the sector expansion at a higher rate. Delta Hospital Ltd. is exploring the opportunities to make full use of the market scope especially in cancer treatment and management. Delta Hospital Limited has setup brand new and latest version TrueBeam Machine which will be increases better services as well as increases revenues. The Company has been operating in the market for a long time and believe to run the business and hold the position with reputation.

**Key operating & financial information:**

The Key operating and financial information for the 2018-19 along with the preceding five years are presented in the page no. 19 of the Annual Report.

**Related Party Transaction:**

Please see the page no. 84 of the Annual Report.

**Pattern of shareholdings:****1. Aggregate number of shares:**

Please see the page no. 75 of the annual report.

**(a) Parent or Subsidiary or Associated Companies and other related parties (name-wise details):**

There is not any Subsidiary or Associated Companies of Delta Hospital Limited.

**(b) Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance and their spouses and minor children (name-wise details):**

Sl.	Name of Shareholders	Potion hold	Number of Shareholding (30-Jun-19)	%	Remarks
1	Mr. Abu Saleh Abdul Muiz	Chairman	1,069,511	3.22	
2	Dr. Syed Mukarram Ali	Director and Managing Director	1,305,000	3.93	
3	Mr. A.Q.M. Nurul Absar	Director	1,423,942	4.29	Death on 7 <sup>th</sup> May 2019
4	Mr. Mir Amjad Hussain	Director	1,045,492	3.15	
5	Mr. Habibur Rahman	Director	1,000,001	3.01	
6	Mrs. Nazmin Showkat Ali	Director	1,814,579	5.46	
7	Mr. Mohd. Shawkat Ali	Director	1,069,511	3.22	
8	Mr. Mahmud Hassan	Director	1,010,000	3.04	
9	Mr. Nurul Huda	Director	1,453,028	4.37	
10	Mr. Md. Obaidur Rahman	Director	1,829,527	5.51	
11	Mr. Mizanur Rahman Sarker	Director	1,062,665	3.20	
12	Mrs. Monowara Ali	Shareholder	324,183	0.98	Spouse of Dr. Syed Mukarram Ali
13	Mrs. Fauzia Khan	Shareholder	3,191	0.01	Spouse of Mr. Mir Amjad Hussain
14	Mrs. Nur Nahar	Shareholder	10,000	0.03	Spouse of Mr. Md. Obaidur Rahman
15	Mr. Md. Bakbul Islam FCMA	Chief Financial Officer	Nil		
16	Mr. Abdul Jalil Miah ACMA	Head of Internal Audit and Compliance	Nil		
17	Mr. Al- Mamun ACS	Company Secretary	Nil		

**(c) Executives:**

As per Corporate Governance Code, Five (5) salaried employees of the company do not hold any share.

**(d) Shareholders holding ten percent (10%) or more voting interest in the company (name-wise details):**

No shareholders of the company holding more than 10% shares of the company.

**Internal Control:**

The Internal Audit function includes undertaking regular reviews of the Delta Hospital's operations, the systems of internal control by performing regular reviews of the business processes to examine and evaluate the adequacy and efficiency of financial and operating controls and highlights significant risks. Management regularly follows up and reviews the status of actions on recommendations made by the internal control. The Board reviews regular reports from the management on the key operating statistics, as well as legal and regulatory matters.

There are policies and procedures in place to ensure compliance with internal control and the prescribed laws and regulations. These policies and procedures are set out in the company's Standard Practice Instruction and are updated from time to time in tune with changes to the business environment and regulatory guidelines.

**Going Concern:**

The Company has adequate resource to continue its operation for foreseeable future. Thus, the Directors are of the opinion that the Company is a going concern and the financial statements are prepared on going concern basis.

**Post Balance Sheet event:**

After the date of reporting period no significant event or situation has arisen which may affect the business or financial statement of the Company for the year 2018-2019

**Proposed Dividend:**

Considering the interest of the shareholders the Board of Directors recommended 12% cash dividend for the year ended 30<sup>th</sup> June 2019 subject to approval in the 33<sup>rd</sup> Annual General Meeting.

**Election of Directors:**

As per Article 81 of the Articles of Association of the Company, one third of the Directors retire by rotation in every general meeting. Accordingly the retiring Directors are Mr. Mir Amjad Hossain, Mr. Habibur Rahman, Mr. Nurul Huda and Dr. Syed Mukarram Ali. As per Article 82 of the Articles of Association of the Company the retiring Directors being eligible, offered themselves for being re-elected as Directors of the Company. A brief resume of the appointed/re-elected Directors are appended in page no.16 to 17.

**Re-Appointment of Managing Director & fix his remuneration:**

The Board of Directors in its meeting held on 12<sup>th</sup> May, 2019 decided to re-appoint Dr. Syed Mukarram Ali as Managing Director of the Company for a further period of 5 (five) years with effect from 1<sup>st</sup> September, 2019 and his salary at Tk. 5,50,000/- per month effective from 1<sup>st</sup> January 2020 and recommended for approval by the shareholders in the ensuing Annual General Meeting. Brief resume and other information of the Managing Director is depicted in Page No.16.

### Re-Appointment of Independent Director

The Board of Directors in its meeting held on 6<sup>th</sup> July, 2019 decided to re-appoint Mr. Kamran Idris Choudhury FCA as Independent Director of the Company for a further period of 3 (three) years with effect from 16<sup>th</sup> July, 2019 as per BSEC Regulations and recommended for approval by the shareholders in the ensuing Annual General Meeting. Brief resume and other information of the above mentioned director is depicted in Page No. 17.

### Audit Committee:

As per Corporate Governance Guidelines of Bangladesh Securities & Exchange Commission, the Board of Directors appointed six (6) members of the Board to form an Audit Committee of which includes two (2) Independent Director and Four (4) Shareholder Directors namely as follows:

Name & Position in the Company	Position in the Audit Committee
Mr. Kamran Idris Choudhury, FCA Independent Director	Chairman
Dr. Syed Mukarram Ali, Director & Managing Director	Member
Mr. Habibur Rahman, Director	Member
Mrs. Nazmin Showkat Ali, Director	Member
Mr. Mizanur Rahman Sarker, Director	Member
Dr. Shamim Jahangir Ahmed, Independent Director	Member

### Nomination & Remuneration Committee:

Pursuant to the BSEC notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 03 June 2018 the Board of Directors appointed four (4) members of the Board to form a Nomination & Remuneration Committee of which includes one Independent Director and three (3) Shareholder Directors namely as follows:

Name & Position in the Company	Position in the NRC
Mr. Kamran Idris Choudhury FCA, Independent Director	Chairman
Dr. Syed Mukarram Ali, Director & Managing Director	Member
Engr. Mir Amjad Hussain	Member
Mr. Abu Saleh Abdul Muiz	Member

### Statutory Auditors:

M/S. FAMES & R Chartered Accountants the Auditors of Delta Hospital Limited has carried out the audit and has submitted their Auditors reports & audited financial statements for the year 2018-2019 and shall retire in this AGM.

M/s. Ahmed Zaker & Co. Chartered Accountants has submitted their expressions of interest to act as an Auditor for the year 2019-2020 and Board accorded approvals in the meeting dated 18<sup>th</sup> January 2020 subject to approvals of the Share holders in the ensuing AGM to be held on 20<sup>th</sup> March 2020.

### Compliance Auditor:

Saifur Enayet & Associates, Cost & Management Accountants, Compliance Auditor of the Company has provided Corporate Governance Compliance Certificate for the fiscal year ended June 30, 2019 with a fixed

remuneration of Tk. 30,000/- and they have expressed their willingness to be reappointed as Compliance Auditor for the fiscal year ended June 30, 2020.

### **Corporate Social Responsibility:**

Delta Hospital Limited defines Corporate Responsibility as operating with integrity at all the times, sustaining our Company's long-term viability while contributing to the present and future well being of all our stakeholders.

The management of the Delta Hospital Limited reiterates its commitment and responsibilities to its clients, shareholders, employees and to the communities. Aspiring to achieve highly professional standards and integrity in all sphere of its operation and functions, managing our financial performances for the benefit of all our stakeholders, making a contribution to the community we live in and avoiding practices that directly or otherwise have a negative impact on others or the environment. We try to carry out these responsibilities properly and endeavor to improve our performance from time to time. We value our shareholders and their rights. We are always committed towards our shareholders to preserve their rights and to enhance their return as much as possible. Considering this fact the management of Delta Hospital gives its best effort to:

- Keep standard operating performance that ranks among the best in the industry;
- Ensure effective corporate governance;
- Provide full and complete financial information;
- Give attractive dividend.

Delta Hospital Limited is committed to be equal opportunity employer, adhering to the highest social standards; the company seeks to provide a defined working environment for all of its employees based on their individual capacity, dignity, qualification and quality. For that purpose Delta Hospital Ltd. is committed to:

- Provide a workplace in which employees are respected;
- Encourage a management style that empowers and develops employees;
- Measure progress in employment practices and employee morale.

Delta Hospital is equally loyal for the responsibility towards the Community and state. Delta Hospital Limited believes that a prosperous community creates a prosperous business by supporting charitable causes.

Further, it is our pleasure to inform you that as part of social commitment Delta Hospital Limited has organized three (3) free Medical Camp programs during the last financial year. In these free Camps, we have given free consultancy services to 2264 number of patients with varieties sort of medical problems like medicine, surgery, gynecology, pediatrics, ENT, skin & VD, orthopedics and ophthalmology. Furthermore, we have allotted 15 beds for poor patients and we have served 555 number of patients in these free beds during the financial 2018-2019.



The number of Board Meetings and the attendance of Directors during the year 2018- 2019 were as follows:

Sl.	Name of Directors	Position	Board Meeting held	Attended	Remarks
1	Mr. Abu Saleh Abdul Muiz	Chairman	7	7	
2	Dr. Syed Mukarram Ali	Director and Managing Director	7	7	
3	Mr. A.Q.M. Nurul Absar	Director	7	0	Death on 7 <sup>th</sup> May 2019
4	Mr. Md. Habibur Rahman	Director	7	5	
5	Mrs. Nazmin Showkat Ali	Director	7	7	
6	Mr. Mohd. Shawkat Ali	Director	7	7	
7	Mr. Nurul Huda	Director	7	7	
8	Mr. Mir Amjad Mussain	Director	7	7	
9	Mr. Mahmud Hassan	Director	7	7	
10	Mr. Md. Obaydur Rahman	Director	7	7	
11	Mr. Mizanur Rahman Sarker	Director	7	7	
12	Mr. Kamran Idris Choudhury FCA	Independent Director	7	2	
13	Dr. Shamim Jahangir Ahmed	Independent Director	7	7	
14	Dr. Chowdhury Habibur Rahman FRCS	Independent Director	7	5	

#### Responsibilities of Managing Director and CFO about Financial Statements review:

The Managing Director and CFO have reviewed the financial statements for the year 2018-2019 before submission to the Board in compliance with Corporate Governance Guidelines issued by Bangladesh Securities and Exchange Commission. A report of Managing Director and CFO in this connection is presented in page no. 31 of this report

**Additional statements under Corporate Governance Code:**

Pursuant to the BSEC notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 03 June 2018 the Directors confirm that:

- a) The financial statements prepared by the management of Delta Hospital Ltd. fairly present its state of affairs, the result of its operations, cash flows and changes in equity.
- b) Proper books of Account of the Company have been maintained.
- c) Appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent Judgment.
- d) International Accounting Standards (IAS), International Financial Reporting Standards (IFRS), as applicable in Bangladesh, have been followed in preparation of financial statements.
- e) The system of internal controls is sound in design and has been effectively implemented and mentioned.
- f) There are no doubts upon the Company's ability to continue as a going concern and the annual accounts have been prepared as going concern basis.
- g) No significant deviations of operating results of the Company from last year to current year have been found.
- h) The key operating and financial data for the last 5 years is enclosed in page no. 19
- i) The pattern of shareholding is disclosed in page no. 75
- j) Related party transactions are disclosed in page no. 84
- k) A brief resume of Directors who have appointed or reappointed in Board and business interest in other organizations have been disclosed in page no. 16 to 17

**Corporate Governance Compliance Report and Compliance Certificate:**

As per Bangladesh Securities and Exchange Commission's Notification No. BSEC/ CMRRCD/ 2006-158/207/Admin/80, dated 3 June 2018 the Corporate Governance Compliance Reports for the year 2018-2019 are appended in page no. 33 to 42 Further, a Certificate of Compliance required under the said guidelines, as provided by Saifur Anayet & Associates, Cost & Management Accountants is also appended in page no. 32 of Annual Report.

**Acknowledgements:**

I would like to express my sincere appreciation thanks to all valued clients, patrons, well wishers and shareholders for their continued support and cooperation. My appreciation also goes to my fellow Members in the Board of Directors of the Hospital for their deliberation and advice in bringing every success for Delta Hospital.

Before I conclude, I would like to extend my special appreciation to our employees for their dedication and hard work without which this performance would not have been possible.

On behalf of the Board of Directors



**Abu Saleh Abdul Muiz**  
Chairman

**Annexure-A**

[As per condition No. 1(5) (xxvi)]  
**DELTA HOSPITAL LIMITED**  
**DECLARATION BY CEO AND CFO**

Date: 19 October, 2019

The Board of Directors  
Delta Hospital Limited

Subject: Declaration on Financial Statements for the year ended on 30 June 2019.

Dear Sirs,

Pursuant to the condition No. 1(5) (xxvi) imposed vide the Commission's Notification No.BSEC/CMRRCD/2006-158/207/Admin/80 dated 3 June 2018 under section 2CC of the Securities and Exchange Ordinance, 1969, we do hereby declare that:

- (1) The Financial Statements of Delta Hospital Limited for the year ended on 30 June 2019 have been prepared in compliance with International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in the Bangladesh and any departure there from has been adequately disclosed;
- (2) The estimates and judgments related to the financial statements were made on a prudent and reasonable basis, in order for the financial statements to reveal a true and fair view;
- (3) The form and substance of transactions and the Company's state of affairs have been reasonably and fairly presented in its financial statements;
- (4) To ensure above, the Company has taken proper and adequate care in installing a system of internal control and maintenance of accounting records;
- (5) Our internal auditors have conducted periodic audits to provide reasonable assurance that the established policies and procedures of the Company were consistently followed; and
- (6) The management's use of the going concern basis of accounting in preparing the financial statements is appropriate and there exists no material uncertainty related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern.

In this regard, we also certify that: -

- (i) We have reviewed the financial statements for the year ended on 30 June 2019 and that to the best of our knowledge and belief:
  - (a) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
  - (b) these statements collectively present true and fair view of the Company's affairs and are in compliance with existing accounting standards and applicable laws.
- (ii) There are, to the best of knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board of Directors or its members.

Sincerely yours,



**Dr. Syed Mukarram Ali**  
Managing Director



**Md. Bakbul Islam, FCMA**  
Chief Financial Officer

**Annexure-B**



**SAIFUR ENAYET & ASSOCIATES**  
**Cost & Management Accountants**

Certificate as per condition no. 1(5)(xxvii)

**CORPORATE OF GOVERNANCE COMPLIANCE CERTIFICATION**

**Report to the Shareholders  
of  
DELTA HOSPITAL LIMITED  
On Compliance on the Corporate Governance Codes  
For the year ended on 30<sup>th</sup> June 2019**

We have examined the compliance status to the corporate governance Code by **Delta Hospital Limited** for the year ended on June 30, 2019. This code relates to the Notification No. BSEC/CMRRCD/2006/158/207/Admin/80, Dhaka, Dated: 03 June 2018 of the Bangladesh Securities and Exchange Commission.

Such compliance with the Corporate Governance Code is the responsibility of the company. Our examination was limited to the procedures and implementation thereof as adopted by the Management in ensuring compliance to the condition of the Corporate Governance Code.

This is scrutiny and verification and an independent audit on compliance of the condition of the corporate Governance Code as well as the provisions of relevant Bangladesh Secretarial Standards (BSS) as adopted by Institute of Chartered Secretaries of Bangladesh (ICSB) in so far those standards are not inconsistent with any condition of this Corporate Governance Code.

We state that we have obtained all the information explanation, which we have required, and after due scrutiny and verification thereof, we report that, in our opinion.

- (a) The company has complied with the condition of the Corporate Governance Code as stipulated in the above mentioned Corporate Governance Code issued by the Commission.
- (b) The company has complied with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) as required by this Code.
- (c) Proper books and records have been kept by the company as required under the Companies Acts, 1994, the securities laws and other relevant laws, and
- (d) The Governance of the company is satisfactory

Place: Dhaka  
Date: February 05, 2020



**For Saifur Enayet & Associates**

Md. Saifur Rahman FCMA  
Principal & CEO  
Cost & Management Accountants

**Annexure-C**

## Status of Compliance with the Corporate Governance Code (CGC) of Delta Hospital Limited for the Year 2018-2019

[As per condition No. 1(5) (xxvii)]

Status of compliance with the conditions imposed by the Commission's Notification No.

BSEC/CMRRCD/2006-158/207/Admin/80, dated 3 June 2018.

(Report under Condition No. 9.00)

Condition No.	Title	Compliance Status		Remarks (if Any)
		Complied	Not Complied	
<b>1.00</b>	<b>Board of Directors(BoD)</b>			
1.(1)	Board Size shall not be less than 5(five) and maximum 20 (twenty)	√		
<b>1.(2)</b>	<b>Independent Director :</b>			
1.2.(a)	At least one-fifth (1/5) of the total number of board of directors shall be Independent Directors (ID);	√		
1.2 (b) (i)	IDs do not hold any share or holds less than 1% shares of the total paid-up shares of the Company	√		
1.2(b) (ii)	ID is not a sponsor and not connected with any sponsor or director or nominated director or shareholder or any of its associates, sister concerns, subsidiaries and parents or holding entities who holds one percent (1%) or more shares of the total paid-up shares and his or her family members shall not hold above mentioned shares;	√		
1.2 (b)(iii)	ID has not been an executive of the company in immediately preceding two financial years;	√		
1.2 (b)(iv)	ID does not have any relationship whether pecuniary or otherwise relationship with the company or its subsidiary/associated companies;	√		
1.2 (b)(v)	ID is not a member or TREC holder, director or officer of any stock exchange;	√		
1.2 (b)(vi)	ID is not a shareholder, director excepting independent director or officer of any member or TREC holder of stock exchange or an intermediary of the capital market;	√		
1.2 (b)(vii)	ID is/was not a partner or an executive of company's audit firms engaged in Statutory Audit or Internal Audit or Special Audit or Compliance Certification of the Codes during preceding three years;	√		
1.2 (b)(viii)	ID shall not be independent director in more than five listed companies;	√		
1.2 (b)(ix)	ID has not been convicted by a court of competent jurisdiction as a defaulter in payment of any loan or any advance to a bank or NBFI;	√		
1.2 (b)(x)	ID has not been convicted for a criminal offence involving moral turpitude;	√		
1.2 ( c )	Appointment of ID shall be done by Board and approved by the shareholders in AGM.	√		
1.2 (d)	The Post of ID cannot remain vacant more than 90 days.	√		
1.2 (e)	The tenure of office of an ID shall be for three(3) years, which may be extended for one(1) tenure only;	√		
<b>1.3</b>	<b>Qualification of Independent Director:</b>			
1.3(a)	Independent Director shall be a knowledgeable individual with integrity who is able to ensure compliance with financial, corporate laws, regulatory requirements and can make meaningful contribution to the business;	√		

1.3(b)(i)	ID is a Business Leader who is/was a promoter or director of an unlisted company having minimum paid-up capital of One Hundred million or any listed company or a member of any national or international chamber of commerce or business association;	√		
1.(3)(b)(ii)	ID is/was a Corporate Leader as top level executive as adopted by the code and a candidate with equivalent position of an unlisted company having minimum paid up capital of Tk. 100.00 million or of a listed company;	√		
1(3)(b)(iii)	ID was Former official of government in the position not below 5th Grade of the national pay scale and educational background of bachelor degree in economics or commerce or business or law;	√		
1(3)(b)(iv)	ID is/was University Teacher who has educational background in Economics or Commerce or Business Studies or Law;	√		
1(3)(b)(v)	ID is/was a professional or an advocate practicing in the HCD of Bangladesh Supreme Court or a CA,CMA, CFA, CCA, CPA and CS or equivalent qualification;	√		
1 (3) ( c )	The ID shall have at least Ten (10) years of experiences in any field mentioned in clause (b);	√		
1 (3) ( d )	Special cases for relaxing qualifications or experiences with prior approval of the Commission;			N/A
<b>1(4)</b>	<b>Duality of Chairperson of the Board of Directors and Managing Director or CEO:</b>			
1(4)(a)	The Position of the Chairman of the Board and the Managing Director (MD) and/or the Chief Executive Officer (CEO) of the Company shall be filled by different Individuals;	√		
1(4)(b)	MD and/or CEO of a listed Company shall not hold the same position in another listed Company;	√		
1(4)(c)	The Chairperson of the Board shall be elected form among the non-executive directors;	√		
1(4)(d)	The Board shall clearly define respective roles and responsibilities of the Chairperson and the Managing Director and/or CEO;	√		
1(4)(e)	In absence of Chairman, the remaining members may elect one from non-executive directors as Chairperson for that particular Board's meeting; the reason of absence shall be duly recorded in the minutes.	√		
<b>1(5)</b>	<b>The Directors' Report to Shareholders :</b>			
1(5)(i)	Industry outlook and possible future developments in the industry;	√		
1(5)(ii)	Segment-wise or product-wise performance;	-	-	Company operates in a single product segment.
1(5)(iii)	Risks and concerns including internal and external risk factors, threat to sustainability and negative impact on environment, if any;	√		
1(5)(iv)	A discussion on Cost of Goods sold, Gross Profit Margin and Net Profit Margin, where applicable;	√		
1(5)(v)	A discussion on continuity of any extraordinary activities and their implications (gain or loss);	-	-	No such activity arose
1(5)(vi)	A detailed discussion and statement on related party transactions;	√	-	
1(5)(vii)	A statement of utilization of proceeds raised through public issues, rights issues and/or any other instruments;	-		N/A



1(5)(viii)	Explanation if the financial results deteriorate after the company goes for IPO, RPO, Rights Offer, Direct Listing, etc.;	-		N/A
1(5)(ix)	Explanation by the Management if significant variance occurs between Quarterly Financial Performance and Annual Financial Statements;	-		No such variance arose
1(5)(x)	Remuneration to Directors including Independent Director;	√		
1(5)(xi)	Statement that financial statements prepared by the management of the issuer present fairly its state of affairs, the result of its operations, cash flows and changes in equity;	√		
1(5)(xii)	Statement that Proper books of account of the issuer company have been maintained;	√		
1(5)(xiii)	Statement that Appropriate accounting policies have been consistently applied in preparation to the financial statements and that the accounting estimates are based on reasonable and prudent judgment;	√		
1(5)(xiv)	Statement that International Accounting Statement (IAS) Bangladesh Accounting Standard (BAS) /International Financial Reporting standard (IFRS), as applicable in Bangladesh, have been followed in preparation of the financial statements and any departure there-from has been adequately disclosed;	√		
1(5)(xv)	Statement that The system of internal control is sound in design and has been effectively implemented and monitored;	√		
1(5)(xvi)	A statement that minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress;	√		
1(5)(xvii)	Statement that There are no significant doubts upon the issuer company's ability to continue as a going concern. If the issuer company is not considered to be a going concern, the fact along with reasons thereof should be disclosed;	√		
1(5)(xviii)	Significant deviations from the last year's operation results of the issuer company shall be highlighted and the reasons there of should be explained;	-	-	No such deviation arose
1(5)(xix)	Key operating and financial data of at least preceding 5 (Five) years shall be summarized;	√		
1(5)(xx)	If the issuer company has not declared dividend (cash or stock) for the year;	-	-	Declared 12% cash dividend
1(5)(xxi)	Board's statement to the effect that no bonus share or stock dividend has been or shall be declared as interim dividend;	-	-	N/A
1(5)(xxii)	The number of Board meetings held during the year and attendance by each Director;	√		
1(5)(xxiii)	A report on the pattern of shareholding disclosing the aggregate (name wise details);	√		
1(5)(xxiii)(a)	Parent/Subsidiary/Associated Companies and other related parties (name wise details);	√		
1(5)(xxiii)(b)	Directors, CEO, Company Secretary, CFO, HIAC and their spouses and minor children (name wise details).	√		

1(5)(xxiii)(c)	Executives.	√		
1(5)(xxiii)(d)	Shareholders holding ten percent (10%) or more voting interest in the company (name wise details);			N/A
<b>1(5)(xxiv)</b>	<b>In case of the appointment/re-appointment of a director the company shall disclose the following information to the shareholders:</b>			
1(5)(xxiv)(a)	A brief resume of the director.	√		
1(5)(xxiv)(b)	Nature of his/her expertise in specific functional areas;	√		
1(5)(xxiv)(c)	Names of the companies in which the person also holds the directorship and the memberships of committees of the Board;	√		
<b>1(5)(xxv)</b>	Management discussion and analysis signed by CEO/MD presenting detail analysis of the company's position and operations along with a brief discussion of changes in the financial statements, among others, focusing on:			
1(5)(xxv)(a)	Accounting policies and estimation for preparation of financial statements;	√		
1(5)(xxv)(b)	Presenting detailed Changes in accounting policies and estimation as well as cash flows on absolute figure for such changes;	√		
1(5)(xxv)(c)	Comparative analysis (including effects of inflation) of financial performance and position as well as cash flows for current financial year with immediate preceding five years explaining reasons thereof;	√		
1(5)(xxv)(d)	Compare such financial performance or results and financial position as well as cash flows with the peer industry scenario;	√		
1(5)(xxv)(e)	Briefly explain the financial and economic scenario of the country and globe;	√		
1(5)(xxv)(f)	Risks and concerns issues related to the financial statements, explaining such risk and concerns mitigation plan of the company;	√		
1(5)(xxv)(g)	Future plan or projection or forecast for company's operation, performance and financial position, with justification thereof, i.e., actual position shall be explained to the shareholders in the next AGM;	√		
1(5)(xxvi)	Declaration or certification by the CEO and the CFO to the Board as required under condition No. 3(3) shall be disclosed as per <b>Annexure-A</b> ;	√		
1(5)(xxvii)	The report as well as certificate regarding compliance of conditions of this Code as required under condition No. 9 shall be disclosed as per <b>Annexure -B</b> and as per <b>Annexure-C</b> .	√		
1(6)	<b>Meeting of the Board of Directors:</b> Conducting Board meetings and recording the minutes of the meetings and keeping required books and records in line BSS as adopted by the ICSB;	√		
<b>1(7)</b>	<b>Code of Conduct for the Chairperson, other Board members and Chief Executive Officer:</b>			
1(7)(a)	The Board shall lay down a code of conduct, based on the recommendation of the Nomination and Remuneration Committee (NRC);	√		
1(7)(b)	The code of conduct as determined by the NRC shall be posted on the website of the company including, among others, prudent conduct and behavior;	√		
<b>2</b>	<b>Governance of Board of Directors of Subsidiary Company:</b>			
2(a)	Provisions relating to the composition of the Board of the holding company shall be made applicable to the composition of the Board of the subsidiary Company;			N/A

2(b)	At least 1 (One) Independent Director of holding company shall be a director on the Board of subsidiary company;			N/A
2(c)	Minutes of subsidiary to be placed in the meeting of holding company;			N/A
2(d)	The minutes of the respective Board meeting of the holding company shall state that they have reviewed the affairs of the subsidiary company also;			N/A
2(e)	The Audit Committee of the holding company shall also review the financial statements in particular the investments made by the subsidiary company.			N/A
<b>3</b>	<b>Managing Director (MD) or Chief Executive Officer (CEO), Chief Financial Officer (CFO), Head of Internal Audit and Compliance (HIAC) and Company Secretary (CS):</b>			
<b>3.1</b>	<b>Appointment:</b>			
3(1)(a)	The Board shall appoint a MD or CEO, CS, CFO and HIAC;	√		
3(1)(b)	The positions of the MD or CEO, CS, CFO and HIAC shall be filled by different individuals;	√		
3(1)(c)	The MD or CEO, CS, CFO, and HIAC of a listed company shall not hold any executive position in any other company at the same time;	√		
3(1)(d)	The Board shall clearly define respective roles, responsibilities and duties of the CFO, the HIAC and the CS;	√		
3(1)(e)	MD or CEO, CS, CFO, and HIAC shall not be removed from their position without approval of the Board and be disseminated to the commission and stock exchange(s).	√		
3 (2)	<b>Requirement to attend Board of Directors' Meetings:</b> MD or CEO, CS, CFO and HIAC shall attend the meetings of the Board;	√		
<b>3.3</b>	<b>Duties of Managing Director (MD) or Chief Executive Officer (CEO) and CFO:</b>			
3(3)(a)(i)	The statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;	√		
3(3)(a)(ii)	The statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards and applicable laws;	√		
3(3)(b)	Certification of CEO and CFO that to the best of their knowledge and belief there was no fraudulent, illegal transactions during the year;	√		
3(3)(c)	The certification of the MD/CEO and CFO shall be disclosed in the Annual Report.	√		
<b>4.</b>	<b>Board of Directors' Committee:</b>			
4 (i)	Audit Committee	√		
4 (ii)	Nomination and Remuneration Committee	√		
<b>5.</b>	<b>Audit Committee:</b>			
<b>5(1)</b>	<b>Responsibility to the Board of Directors</b>			
5(1) (a)	Company shall have an Audit Committee as a sub-committee of the Board.	√		
5(1) (b)	Audit Committee shall assist the Board in ensuring that the financial statements reflect true and fair view of the state of affairs of the Company and in ensuring a good monitoring system within the business;	√		

5(1) (c)	Audit Committee shall be responsible to the Board. The duties of Audit Committee shall be clearly set forth in writing.	√		
<b>5.2</b>	<b>Constitution of the Audit committee:</b>			
5(2) (a)	The Audit Committee shall be composed of at least 3 (three) members.	√		
5(2) (b)	Board shall appoint members of the Audit Committee who shall be non-executive directors of the company excepting Chairperson of the Board and shall include at least one Independent director (ID);	√		
5(2) (c)	All members of the Audit Committee should be “financially literate” and at least 1 (one) member shall have accounting or related financial management background and 10 years of such experience;	√		
5(2) (d)	When the term of service of the Committee members expires or there is any circumstance causing any Committee member to be unable to hold office until expiration of the term of service, thus making the number of the Committee members to be lower than the prescribed number of 3 (three) persons, the Board of Directors shall appoint the new Committee member(s) to fill up the vacancy(ies) immediately or not later than 1 (one) month from the date of vacancy(ies) in the Committee to ensure continuity of the performance of work of the Audit Committee;	√		
5(2) (e)	The Company Secretary shall act as the Secretary of the Audit Committee;	√		
5(2)(f)	The quorum of the Audit Committee meeting shall not constitute without at least 1 (one) independent director;	√		
<b>5.3</b>	<b>Chairperson of the Audit Committee:</b>			
5(3)(a)	The Board of Directors shall select 1 (one) member of the Audit Committee to be Chairman of the Audit Committee, who shall be an independent director;	√		
5(3)(b)	Election of Chairman of the particular meeting in absence of regular Chairperson of Audit Committee recording the reasons of such absence in the minutes.	-	-	No such incidence arose
5(3)(c)	Chairperson of the Audit Committee shall remain present in the AGM.	√		
<b>5.4</b>	<b>Meeting of the Audit Committee:</b>			
5(4)(a)	The Audit Committee shall conduct at least 4 meetings in a financial year.	√		
5(4)(b)	Quorum of Audit Committee, presence of 2 or 2/3 members whichever is higher, where presence of an ID is a must.	√		
<b>5.5</b>	<b>Role of Audit Committee:</b>			
5(5)(a)	Oversee the financial reporting process;	√		
5(5)(b)	Monitor choice of accounting policies and principles;	√		
5(5)(c)	Internal Audit and Compliance process to ensure that it is adequately resourced;	√		
5(5)(d)	Oversee hiring and performance of external auditors;	√		
5(5)(e)	Hold meeting with the auditors, review the annual financial statements before submission to the Board for approval or adoption;	√		

5(5)(f)	Review along with the management, the annual financial statements before submission to the board for approval;	√		
5(5)(g)	Review along with the management, the quarterly and half yearly financial statements before submission to the board for approval;	√		
5(5)(h)	Review adequacy of internal audit function;	√		
5(5)(i)	Review the management's discussion and analysis before disclosing in the Annual Report;	√		
5(5)(j)	Review statement of all related party transactions submitted by the management;	√		
5(5)(k)	Review management letters or letter of Internal Control weakness issued by statutory auditors;	√		
5(5)(l)	Oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external auditors;	√		
5(5)(m)	Oversee whether the proceeds raised IPO or RPO or Rights Share Offer have been utilized per the purposes stated in relevant offer document or prospectus approved by the Commission;	-	-	N/A
<b>5.6</b>	<b>Reporting of the Audit Committee:</b>			
<b>5.6 (a)</b>	<b>Reporting to the Board of Directors</b>			
5(6)(a)(i)	The Audit Committee shall report on its activities to the Board.	√		
<b>5(6)(a)(ii)</b>	<b>The audit committee shall immediately report to the board on the following findings, if any:-</b>			
5(6)(a)(ii)(a)	Report on conflicts of interests;	-	-	No such incidence arose
5(6)(a)(ii)(b)	Suspected or presumed fraud or irregularity or material defect identified in the internal audit and compliance process;	-	-	No such incidence arose
5(6)(a)(ii)(c)	Suspected infringement of laws, regulatory compliance including securities related laws, relies and regulation;	-	-	No such incidence arose
5(6)(a)(ii)(d)	Any other matter which the Audit Committee deems necessary shall be disclosed to the Board immediately;			No such incidence arose
5.6 (b)	<b>Reporting to the Authorities:</b> If any material impact on the financial condition and results of operation, unreasonably ignored by the management;			No such incidence arose
5.7	<b>Reporting to the Shareholders and General Investors:</b> Report on the activities carried out by the Audit Committee, including any report made to the Board of Directors under condition 5(6)(a)(ii);	√		
<b>6</b>	<b>Nomination and Remuneration Committee (NRC):</b>			
<b>6.1</b>	<b>Responsibility to the Board of Directors</b>			
6(1)(a)	The company shall have a NRC as a sub-committee of the Board.	√		
6(1)(b)	The NRC shall assist the Board in formulation of the nomination criteria or policy for determining qualifications, positive attributes experiences and independence of directors and top level executive as well as a policy for formal process of considering remuneration of directors, top level executive;	√		
6(1)(c)	The Terms of Reference (ToR) of the NRC shall be clearly set forth in writing covering the areas stated at the condition No. 6(5)(b);	√		

<b>6.2</b>	<b>Constitution of the NRC</b>			
6(2)(a)	The Committee shall comprise of at least three members including an independent director (ID);	√		
6(2)(b)	All members of the Committee shall be non-executive directors;	√		
6(2)(c)	Members of the Committee shall be nominated and appointed by the Board;	√		
6(2)(d)	Board shall have authority to remove and appoint any member of the committee;	√		
6(2)(e)	In case of death, resignation, disqualification, or removal of any member of the Committee or in any other cases of vacancies, the board shall fill the vacancy within 180 (one hundred eighty) days of occurring such vacancy in the Committee;	-		No such incidence occurred
6(2)(f)	The Chairperson of the Committee may appoint or co-opt any external expert and/or member(s) of staff to the Committee as advisor who shall be non-voting member, if the Chairperson feels that advice or suggestion from such external expert and/or member(s) of staff shall be required or valuable for the Committee;	-	-	No such appointment made or Co-opted
6(2)(g)	The company secretary shall act as the secretary of the committee;	√		
6(2)(h)	The quorum of the NRC meeting shall not constitute without attendance of at least an independent director;	√		
6(2)(i)	No member of the NRC shall receive, either directly or indirectly, any remuneration for any advisory or consultancy role or otherwise, other than Director's fees or honorarium from the company;	√		
<b>6.3</b>	<b>Chairperson of the NRC</b>			
6(3)(a)	The Board shall select 1 (one) member of the NRC to be Chairperson of the Committee, who shall be an independent director;	√		
6(3)(b)	In the absence of the Chairperson of the NRC, the remaining members may elect one of themselves as Chairperson for that particular meeting, the reason of absence of the regular Chairperson shall be duly recorded in the minutes;	-	-	No such absence occurred during the year
6(3)(c)	The Chairperson of the NRC shall attend the annual general meeting (AGM) to answer the queries of the shareholders;	√		
<b>6.4</b>	<b>Meeting of the NRC</b>			
6(4)(a)	The NRC shall conduct at least one meeting in a financial year;	√		
6(4)(b)	The Chairperson of the NRC, may convene any emergency meeting upon request by any member of the NRC;	-	-	No such meeting required to call
6(4)(c)	The quorum of the meeting of the NRC shall be constituted in presence of either two members or two third of the members of the Committee, whichever is higher, where presence of an independent director is must as required under condition No. 6(2)(h);	√		
6(4)(d)	The proceedings of each meeting of the NRC shall duly be recorded in the minutes and such minutes shall be confirmed in the next meeting of the NRC;	√		



<b>6.5</b>	<b>Role of NRC</b>			
6(5)(a)	NRC shall be independent and responsible/accountable to the Board and to the shareholders;	√		
6(5)(b)(i)(a)	NRC shall oversee, formulate & recommend to the Board regarding the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable directors to run the company successfully;	√		
6(5)(b)(i)(b)	Relationship of remuneration to performance is clear and meets appropriate performance benchmarks;	√		
6(5)(b)(i)(c)	Remuneration to directors, top level executive involves a balance between fixed and incentive pay reflecting short and long term performance objectives appropriate to the working of the company and its goals;	√		
6(5)(b)(ii)	Devising a policy on Board's diversity taking into consideration age, gender, experience, ethnicity, educational background and nationality;	√		
6(5)(b)(iii)	Identifying persons who are qualified to become directors and who may be appointed in top level executive position in accordance with the criteria laid down, and recommend their appointment and removal to the Board;	√		
6(5)(b)(iv)	Formulating criteria for evaluation of performance of independent directors and the Board;	√		
6(5)(b)(v)	Identifying the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria;	√		
6(5)(b)(vi)	Developing recommending and reviewing annually the company's human resources and training policies.	√		
6(5)(c)	The company shall disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC at a glance in its annual report.	√		
<b>7</b>	<b>External or Statutory Auditors</b>			
<b>7(1)</b>	<b>The issuer company shall not engage its external or statutory auditors to perform the following services of the company, namely:-</b>			
7(1)(i)	Appraisal or valuation services or fairness opinions;	√		
7(1)(ii)	Financial information systems design and implementation;	√		
7(1)(iii)	Book-keeping or other services related to the accounting records or financial statements;	√		
7(1)(iv)	Broker-dealer services;	√		
7(1)(v)	Actuarial services;	√		
7(1)(vi)	Internal audit services or special services;	√		
7(1)(vii)	Any other service that the Audit Committee determines;	√		
7(1)(viii)	Audit or certification services on compliance of corporate governance as required under condition No. 9(1);	√		
7(1)(ix)	Any other service that may create conflict of interest.	√		
7(2)	No partner or employees of the external audit firms shall possess any share of the company they audit at least during the tenure of their audit assignment of that company; his or her family shall not hold any shares in the said company.	√		

7(3)	Representative of external or statutory auditors shall remain present in the Shareholders' Meeting (Annual General Meeting or Extraordinary General Meeting) to answer the queries of the shareholders;	√		
<b>8</b>	<b>Maintaining a website by the company</b>			
8(1)	The company shall have an official website linked with the website of the stock exchange.	√	-	
8(2)	The company shall keep the website functional from the date of listing.	√	-	
8(3)	The company shall make available the detailed disclosures on its website as required under the listing regulations of the concerned stock exchange(s).	√	-	
<b>9</b>	<b>Reporting and Compliance of Corporate Governance</b>			
9(1)	The company shall obtain a certificate from a practicing Professional Accountant/Secretary (Chartered Accountant/ Cost and Management Accountant / Chartered Secretary) other than its statutory auditor or audit firm on yearly basis regarding compliance of conditions of Corporate Governance Code of the Commission and shall such certificate shall be disclosed in the Annual Report.	√		
9(2)	The professional who will provide the certificate on compliance of Corporate Governance shall be appointed by the Shareholders in the AGM.	√		
9(3)	The directors of the company shall state, in accordance with the Annexure-C attached, in the directors' report whether the Company has complied with these conditions or not.	√		

## Photo Album of 32<sup>nd</sup> AGM, 2019



*The Chairman Mr. Abu Saleh Abdul Muiz, Managing Director Dr. Syed Mukarram Ali and CFO Mr. Md. Bakbul Islam, FCMA*



*The Chairman, Managing Director, Directors, CFO and Company Secretary*



## Photo Album of 32<sup>nd</sup> AGM, 2019



*A Partial view of shareholders' present at the 32<sup>nd</sup> Annual General Meeting*



*A Partial view of shareholders' present at the 32<sup>nd</sup> Annual General Meeting*

- **Doctors**
- **Pathologists**
- **Medical Physicists**
- **Medical Services**

## Department of Oncology



**Dr. Parvin Akhter Banu**

MBBS  
Board Certified in Radiation Oncology (Shiraz, Iran)  
Ex. Asst. Professor Ahvaz Medical University, Iran  
**Chief Consultant Oncologist**



**Dr. (Lt. Col.) M. S. Sarwar Alam (Rtd.)**

MBBS, DMRT, FCPS  
Clinical Oncologist  
**Senior Consultant**



**Prof. Dr. Kazi Manzur Kader**

MBBS, DMRT, MSc, FACP, FRCP (Glasgow)  
Fellowship- Radiation Oncology  
**Senior Consultant & Head**



**Dr. Md. Rezaul Sharif**

MBBS (MMC), M.Phil (Radiotherapy)  
Certified Training in Oncology  
Tata Memorial Hospital, Mumbai, India  
**Senior Consultant**



**Dr. Naheed Rukhsana**

MBBS, FCPS (Radiotherapy)  
**Senior Consultant**



**Dr. Lutfun Nahar**

MBBS, M.Phil (Radiotherapy)  
**Senior Consultant**



**Dr. Mirza Md. Shakhawat Hossain**

MBBS, FCPS (Radiotherapy)  
**Senior Consultant**



**Dr. Arman Reza Chowdhury**

MBBS, FCPS (Radiotherapy)  
**Consultant**



**Dr. Anjan Kumar Das**

MBBS, M.Phil (Radiotherapy)  
**Junior Consultant**



**Dr. Shamima Afroz Trina**

MBBS, FCPS (Radiotherapy)  
**Junior Consultant**



**Dr. Ishrat Sultana**

MBBS, FCPS (Radiotherapy)  
**Junior Consultant**



**Dr. Anannya Sarkar**

MBBS (DU), MCPS, FCPS (Radiotherapy)  
**Junior Consultant**



**Dr. Tanzina Hossain**

MBBS, MD (Medical Oncology)  
**Registrar**



**Dr. Negar Mahjabin**

MBBS, FCPS (Radiotherapy)  
**Registrar**



## Department of Surgical Oncology



**Dr. Tangera Akter (Neetu)**  
MBBS, MS (Surgical Oncology)  
Cancer Surgery Specialist  
**Junior Consultant**

## Department of Haematology



**Dr. Amin Lutful Kabir**  
MBBS, M.Phil, FCPS (Haematology)  
Associate Professor, BSMMU  
**Senior Consultant**

## Department of Medicine



**Prof. (Dr.) Syed Wahidur Rahman**  
MBBS (Dhaka), FCPS (Medicine)  
Trained in Neurology (Australia)  
Physician & Neurologist  
**Professor**



**Dr. Syeda Adib Sultana**  
MBBS, FCPS (Medicine)  
**Senior Consultant**



**Dr. Sadia Islam**  
MBBS (DU), FCPS (Medicine)  
**Associate Professor & Head**



**Dr. Sumiya Bent Kalam**  
MBBS, MCPS, FCPS (Medicine)  
**Assistant Professor**



**Dr. Md. Ashraful Islam**  
MBBS (Dhaka),  
**Resident Physician (R.P.)**

## Department of Cardiology



**Dr. Mohammad Abu Kauser**  
MBBS, D-Card. (DU); MD Cardiology (DU)  
**Senior Consultant**

## Department of Gastroenterology



**Dr. Nigar Sultana**  
MBBS, MPH, FCPS (Gastroenterology)  
**Junior Consultant**

## Department of Psychiatry



**Dr. Md. Harunur Rashid**  
MBBS, M.Phil (Microbiology)  
MCPS, FCPS (Psychiatry)  
Psychiatric Diseases Specialist  
**Associate Professor**

## Department of Transfusion Medicine



**Dr. Md. Rafiqul Haque**  
MBBS, MD (Transfusion Medicine & Immunohaematology)  
**Consultant**  
Transfusion Medicine & Immunohaematology

## Department of Dermatology & Venereology



**Dr. Ayesha Siddiqua**  
MBBS, DDV, FCPS (Skin)  
Fellowship Training in Skin Surgery LASER  
(IOD, Thailand)  
**Associate Professor & Head**



**Dr. Md. Asif Imran Siddique**  
MBBS, DDV (Thailand)  
Trained in Laser & Cutaneous Surgery-Thailand  
**Resident Physician (R.P.)**

## Department of Paediatrics



**Prof. (Dr.) Md. Rafiqul Islam**  
MBBS, FCPS (Paediatrics)  
**Professor & Head**



**Dr. Nibedita Paul**  
MBBS, FCPS (Paediatrics)  
**Associate Professor**



**Dr. Nadia Nusrat**  
MBBS, FCPS (Paediatrics)  
**Assistant Professor**



**Dr. Sara Bilkis**  
MBBS, FCPS (Paediatrics)  
**Resident Physician (R.P.)**

## Newborn & Neonatal Intensive Care Unit



**Dr. A.K.M Khairul Anam Chowdhury**  
MBBS (D.U.), MCPS (Paediatrics), DCH (Ireland)  
**Consultant & In-charge**



**Dr. Tania Afrin**  
MBBS, DCH (DMC)  
**Registrar**

## Department of Surgery



**Prof. Hasan Md. Abdur Rouf**  
MBBS (DMC), FCPS (Surgery)  
**Professor**



**Prof. Dr. Tapes Kumar Paul**  
MBBS (DMC), FCPS (Surgery)  
MS (Surgical Oncology)  
**Professor & Head**



**Dr. Md. Mostafizur Rahman**  
MBBS, MS (Surgery)  
**Associate Professor**



**Dr. Shayda Ali**  
MBBS, FCPS (Surgery)  
**Assistant Professor**



**Dr. Russel Ahmed Khan Lodi**  
MBBS, MCPS (Surgery)  
**Resident Surgeon (R.S)**

## Department of Orthopaedic Surgery



**Prof. Dr. Md. Abdul Quader**  
MBBS, D.Ortho, M.S (Ortho)  
**Professor & Head**



**Dr. Md. Shoriful Islam**  
MBBS, D-Ortho  
(Trained in Plastic & Reconstructive Surgery)  
**Assistant Professor**



**Dr. Md. Masud Rana**  
MBBS (DU)  
**Registrar**

## Department of ENT & Head-Neck Surgery



**Prof. Dr. Mohammed Yousuf**  
MBBS, MCPS, FCPS (ENT & Head-Neck Surgery)  
**Professor & Head**



**Dr. K.M. Reza-ul Haq**  
MBBS, FCPS (ENT & Head-Neck Surgery)  
**Assistant Professor**



**Dr. Kaosar-e-Rabbi**  
MBBS  
**Registrar**

## Department of Ophthalmology



**Prof. Dr. Md. Shafiqul Alam**  
MBBS (DU), DO, FCPS (Eye), MS (Eye)  
**Professor**



**Dr. Nazneen Bari**  
MBBS, D.O (Eye)  
**Associate Professor & Head**



**Dr. Md. Monwarul Azim**  
MBBS  
**Registrar**

## Department of Gynae & Obs.



**Prof. Dr. Ferdous Ara (Shuchi)**  
MBBS, FCPS (Gynae & Obs.)  
**Professor & Head**



**Dr. Sufia Begum (Shampy)**  
MBBS, FCPS (Gynae & Obs.)  
**Associate Professor**



**Dr. Mst. Nazmun Nahar Mina**  
MBBS, FCPS (Gynae & Obs.)  
**Assistant Professor & R.S.**



**Dr. Shamsunnahar Rikta**  
MBBS, MCPS, FCPS, (Gynae & Obs.)  
**Assistant Professor**



**Dr. Samira Areen**  
MBBS, FCPS (Gynae & Obs.)  
**Registrar**



**Dr. Shahnaz Parvin**  
MBBS, DGO  
**Registrar**



**Dr. Mahin Rahman**  
MBBS, DGO, MCPS (Gynae & Obs.)  
**Resident Surgeon (R.S)**

## Department of Radiology & Imaging



**Prof. (Dr.) Shaikh Shofiur Rahman**  
MBBS, M.Phil  
**Professor, Sr. Consultant & Head**



**Dr. Rafia Parveen**  
MBBS, M.Phil  
**Associate Professor & Consultant**



**Dr. Taposhi Sarker**  
MBBS, FCPS (Radiology & Imaging)  
**Assistant Professor**

## Dental Unit



**Prof. Dr. Al Mamoon Ferdousi**

BDS (Dhaka), GDCS (London), MDSC (Eng.), FFDRCS (Ire.),  
FMSAC (Glas), FRSM (London), FICD (USA), FICS (USA)  
**Founder Advisor & Supernumerary Professor**  
Dental Unit



**Dr. Ayesha Siddika**

BDS, MPH, MCPS, FCPS (Oral & Maxillofacial Surgery)  
**Associate Professor (Hon.)**  
Department of Oral & Maxillofacial Surgery



**Dr. Farhana Hoq Susta**

BDS, MS (Prosthodontics)  
Head of Dental Unit  
**Assistant Professor**



**Dr. Shaikh Abdullah Al-Jami**

BDS (DU), MPH (BSMMU)  
**Assistant Professor & Head**  
Department of Dental Public Health



**Dr. Shafin Zaman**

BDS, MPH, MCPS  
**Assistant Professor**  
Department of Pediatric Dentistry



**Dr. Sabiha Alam**

BDS, MPH, FCPS (Oral & Maxillofacial Surgery)  
**Assistant Professor**  
Department of Oral & Maxillofacial Surgery



**Dr. Asheque Rahman**

BDS, Ms. (Prosthodontics)  
**Assistant Professor**  
Department of Prosthodontics



**Dr. Moutithi Sen**

BDS, FCPS (Orthodontics)  
**Assistant Professor, Orthodontics**  
Department of Orthodontics

## Department of Anaesthesia



**Prof. Dr. Paresh Chandra Sarker**

DA, FCPS (Anaesthesia)  
**Senior Consultant & Head**



**Dr. Md. Nazmul Kayes**

MBBS, DA  
**Associate Professor**



**Dr. Ambia Afza**

MBBS, DA  
**Registrar**



## Department of ICU & HDU



**Prof. Dr. Refat Hossain Malik**  
MBBS, DA, FCPS ( Anaesthesia)  
**Senior Consultant & Head**

## Department of Palliative Care Unit (PCU)



**Dr. N. M. Nazmul Kabir Prodhan**  
MBBS, DA (DU)  
Fellowship in Palliative Medicine (IPM, India)  
In-Charge, Palliative Care Unit (PCU)  
**Associate Professor & Consultant**

## Department of Pathology



**Prof. (Dr.) Syed Mukarram Ali**  
MBBS (Dhaka), M.Phil (Karachi)  
D.Path (England), DCP (London)  
FRC-Path (London)  
**Chief Consultant, Pathology**



**Prof. Dr. Munir Hassan**  
MBBS (DU), DCM (London)  
**Senior Consultant, Microbiology**



**Prof. Dr. Syed Salahuddin Ahmed**  
MBBS, Ph.D (Japan)  
WHO Fellow (Cytopathology), Tata, India  
**Senior Consultant, Histopathology**



**Dr. Kuazi Dil Afroz**  
MBBS, Ph.D (Japan)  
**Associate Professor & Consultant  
Histopathology**



**Prof. Dr. Nasim Ahmed**  
MBBS, M.Phil (Pathology)  
**Consultant, Pathology**



**Dr. Nadira Majid**  
MBBS, MD (Pathology)  
**Associate Professor & Junior Consultant  
Pathology**



**Dr. Afia Akhter**  
MBBS, MD (Pathology)  
**Associate Professor & Junior Consultant  
Pathology**



**Dr. Mahamudul Huda**  
MBBS, MD (Pathology)  
**Junior Consultant**

## Department of Medical Physics



**S. M. Enamul Kabir**  
M.Sc (N.U)  
**Principal Medical Physicist & Coordinator**



**Md. Abdul Jobbar**  
M.Sc (D.U)  
**Principal Medical Physicist**



**Md. Mostafizur Rahman**  
M.Sc (Gono University)  
**Senior Medical Physicist**



**Md. Shariful Islam**  
M.Sc (N.U)  
**Medical Physicist**



**Morsheda Alam**  
M.Sc (Gono University)  
**Medical Physicist**



**Md. Abu Kausar**  
M.Sc ((Gono University)  
**Medical Physicist**



**Rahnuma Nur Nawrin**  
M.Sc (Gono University)  
**Medical Physicist**

## Medical Services

### Our Medical Services:

- Outdoor medical treatment with specialized doctors and consultants
- Out door (OPD) Patient management
- Indoor Patient (IPD) management
- Intensive care unit (ICU)
- High Dependency Unit (HDU)
- Neonatal Intensive Care Unit (NICU)
- Palliative care unit (PCU)
- 24 Hours Emergency Medical Service
- 24 Hours Pharmacy Service
- 24 Hours Blood Bank Service
- Most up-to-date Operation theatre (Total 07 O.T.)
- Radiology and Imaging
- Physiotherapy

### Our Specialized Oncology (Cancer) Treatment:

- Cancer Detection and Management
- Radiotherapy
- Chemotherapy
- Cancer Surgery
- Cancer Counseling

### Our Radiotherapy machines are most sophisticated & advanced technology, these are:

- Linac TrueBeam Linear Accelerator Machine
- 3D CRT Linear Accelerator machine
- Cobalt-60 machine
- Brachytherapy HDR (High dose rate) machine
- Simulator
- CT Simulator

### Our Specialized General Treatment:

- Medicine ■ Neuro-Medicine ■ Cardiology ■ Gastroenterology
- Psychiatry ■ General Surgery ■ Surgical Oncology ■ Gynaecology
- Gynae & Obs. ■ Paediatrics ■ Orthopaedics ■ Eye ■ ENT
- Skin & VD ■ Paediatric Surgery ■ Dental department

### Diagnostic Facilities:

- 4D Ultrasound ■ Endoscopy ■ C T Scan ■ Digital X-ray
- ECG ■ Echocardiogram ■ Mammogram
- All Pathological Investigations

### We are giving maximum facilities in our services Our facilities are:

### Our indoor Cabin & Ward facilities are:

- Intensive Care Unit ■ High Dependency Unit ■ Palliative Care Unit
- VIP Cabin ■ A/C Cabin ■ Non A/C Cabin ■ A/C Ward ■ Non A/C Ward
- modern OT facilities with Post Operative Ward
- Day Care for Chemotherapy.

### Pathology Services:

### Our modern pathological laboratory can do all types of tests:

- Clinical Pathology
- Hematology
- Bio Chemistry
- Microbiology
- Cytology
- FNAC
- Histopathology
- Tumor marker
- Frozen section biopsy
- Chromosome Study
- Blood transfusion service
- Immunology
- Virology
- Serology
- Hormone test
- ER
- PR
- HER-2



## Auditors' Report

## Independent Auditors' Report To The Shareholders of Delta Hospital Limited

### Report on the Audit of the Financial Statements

#### Opinion

We have audited the financial statements of Delta Hospital Limited, which comprise the

Statement of Financial Position as at June 30, 2019 and the Statement of Profit or Loss and

other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year then ended and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the Company as at June 30, 2019 and of its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs).

#### Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our

responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) together with the ethical requirements that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these ethical requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

SN	Risk	Our response to the risk
1.	<p><b>Appropriateness of revenue recognition and disclosures on the impact of the initial application of IFRS 15.</b></p> <p>Refer to note 22 to the financial statements.</p> <p>Revenue upon transfer of control as per the newly adopted IFRS 15– Revenue from Contracts with Customers. The Group has reported total revenue of BDT 653,300,110.</p>	<ul style="list-style-type: none"> <li>Assessed the environment of the measurement as well another relevant systems supporting to the accounting of revenue.</li> <li>Assessed manual as well as application controls supporting revenue recognition.</li> <li>Assessed the invoicing and measurement systems up to entries in the general ledger.</li> </ul>

SN	Risk	Our response to the risk
	<p>The Company's primary customers are its corporate customers who are entitled to get competitive rates for goods and services invoiced.</p> <p>Given the significance and complexities involved in the accounting of Revenue, appropriate recognition of revenue has been considered as a key audit matter.</p>	<ul style="list-style-type: none"> <li>● Examined customer invoices and receipts of payment on a test basis.</li> <li>● Assessed the design of the processes set up to account for the transactions in accordance with the new standard.</li> <li>● Assessed whether any adjustments is required to be made to opening balances due to the adoption of the new standard.</li> </ul>
2.	<p><b>Addition to Property, Plant and Equipment</b></p> <p>Refer to note 03 to the financial statements.</p> <p>The Company made significant addition to Property Plant &amp; Equipment by amounting BDT 251,738,920.</p>	<p>Our audit procedures included, among others, considering the risk of addition to Property, Plant and Equipment associated with the different types of asset:</p> <ul style="list-style-type: none"> <li>● We critically assessed and verified the Company's policy of asset addition.</li> <li>● We assessed the appropriateness of the value of the assets.</li> <li>● We also recalculated the depreciation to assess the sensitivity of the key assumptions including depreciation rate.</li> </ul>

## Other Information

Management is responsible for other information. Other information comprises the information including Director's report included in the annual report but does not include in the financial statements and our auditors' report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. Based on our audit we have nothing to report in this regard

## Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing as applicable matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.



## Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements

As part of an audit in accordance with ISAs, we exercise professional judgments and maintain professional skepticism throughout the audit. We also report that:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and based on the audit evidence obtained, whether a

material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or if such disclosures are inadequate to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Company's financial statements including the disclosures and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence and where applicable related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

### **Report on other Legal and Regulatory Requirements**

In accordance with the Companies Act 1994 and the Securities and Exchange Rules 1987, we also report the following:

a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;

b) in our opinion, proper books of accounts as required by law have been kept by the Company so far as it appeared from our examination of these books;

c) the statements of financial position and statements of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of accounts and returns; and

d) the expenditure incurred was for the purposes of the Company's business.

Dated : October 19, 2019  
Place : Dhaka, Bangladesh

  
**FAMES & R**  
Chartered Accountants

**DELTA HOSPITAL LIMITED**  
**STATEMENT OF FINANCIAL POSITION**

As at June 30, 2019

Particulars	Notes	Amount in Taka	
		30 -June - 19	30 -June - 18
<b>ASSETS</b>			
<b>Non-Current Assets</b>		<b>2,645,569,807</b>	<b>2,190,871,466</b>
Property, Plant & Equipment	3.00	2,162,316,707	1,990,368,177
Capital Work in process-Building	4.00	226,151,805	172,731,848
Stock of Furniture & Fixture	4.01	28,547,122	27,771,441
Stock of Machinery	4.02	228,554,173	-
<b>Current Assets</b>		<b>266,930,844</b>	<b>397,963,496</b>
Inventories	5.00	35,440,028	32,126,809
Trade and Other Receivable	6.00	30,711,782	20,575,007
Advances, Deposits & Prepayments	7.00	152,073,704	215,107,659
Loan to Globex Pharmaceuticals Ltd.	8.00	10,000,000	10,000,000
Investment in Shares-Globex Pharmaceuticals Ltd.	9.00	34,316,517	34,316,517
Cash & Cash Equivalents	10.00	4,388,813	85,837,504
<b>Total Assets</b>		<b>2,912,500,651</b>	<b>2,588,834,962</b>
<b><u>SHAREHOLDER'S EQUITY AND LIABILITIES</u></b>			
<b>Shareholders Equity</b>		<b>1,522,595,928</b>	<b>1,491,935,170</b>
Share Capital	11.00	332,126,940	332,126,940
Share Premium	12.00	25,690,410	25,690,410
Retained Earnings	13.00	194,053,229	159,925,420
Revaluation Reserve	14.00	970,725,349	974,192,400
<b>Long -Term Liabilities</b>		<b>913,093,613</b>	<b>703,721,077</b>
Long-Term Borrowings / Loan	15.00	754,554,735	559,311,976
Deferred Tax	16.00	158,538,878	144,409,101
<b>Current Liabilities</b>		<b>476,811,110</b>	<b>393,178,715</b>
Short -Term Loan	17.00	136,460,323	86,106,156
Current Maturity of Long Term Loan	15.00	199,967,088	165,093,072
Accrued Expenses	18.00	53,121,250	50,886,006
Accounts Payable	19.00	29,521,342	32,422,294
Provision for Current Tax	20.00	46,569,571	48,764,516
Other Liabilities	21.00	11,171,536	9,906,671
<b>Total Equity &amp; Liabilities</b>		<b>2,912,500,651</b>	<b>2,588,834,962</b>
<b>Net Asset Value Per Share with revaluation</b>	28.01	<b>45.84</b>	<b>44.92</b>
<b>Net Asset Value Per Share without revaluation</b>	28.02	<b>16.62</b>	<b>15.59</b>

The accompanying notes form an integral part of these financial statements.

  
Chairman

  
Managing Director

  
Company Secretary

Signed in terms of our separate report of even date.

Date: October 19, 2019  
Place: Dhaka

  
**FAMES & R**  
Chartered Accountants

**DELTA HOSPITAL LIMITED**  
**STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME**  
For the year ended June 30, 2019


Particulars	Notes	Amount in Taka	
		30 -June - 19	30 -June - 18
Revenue	22.00	653,300,110	592,242,162
Operating Expenses	23.00	(397,318,527)	(351,015,239)
<b>Gross Profit</b>		<b>255,981,583</b>	<b>241,226,923</b>
General and Administrative Expenses	24.00	(121,578,393)	(107,988,895)
<b>Profit from Operations</b>		<b>134,403,190</b>	<b>133,238,028</b>
Non-Operating Income	25.00	13,192,075	15,571,827
Financial Expenses	26.00	(48,024,004)	(34,979,741)
<b>Profit before Contribution to WPPF</b>		<b>99,571,261</b>	<b>113,830,115</b>
WPPF & Welfare Fund	18.01	(4,741,489)	(5,420,482)
<b>Net Profit Before Tax</b>		<b>94,829,772</b>	<b>108,409,633</b>
<b>Provision for Tax</b>		<b>24,925,614</b>	<b>39,409,800</b>
Current Tax	20.01	10,184,004	26,693,151
Deferred Tax	16.00	14,741,610	12,716,649
<b>Net Profit after Tax</b>		<b>69,904,158</b>	<b>68,999,833</b>
<b>Other Comprehensive Income:</b>		<b>-</b>	<b>-</b>
<b>Total Comprehensive Income</b>		<b>69,904,158</b>	<b>68,999,833</b>
<b>Earning Per Share (EPS)</b>	27.00	<b>2.10</b>	<b>2.08</b>

The accompanying policies and explanatory notes 1-37 form an integral part of these financial statements.

  
Chairman

  
Managing Director

Signed in terms of our separate report of even date.

  
Company Secretary

Date: October 19, 2019  
Place: Dhaka

  
**FAMES & R**  
Chartered Accountants

**DELTA HOSPITAL LIMITED**  
**STATEMENT OF CHANGES IN EQUITY**  
For the year ended June 30, 2019

Amount in Taka

Particulars	Share Capital	Share Premium	Revaluation Reserve	Retained Earnings	Total
Balance as at July 01, 2018	332,126,940	25,690,410	974,192,400	159,925,420	1,491,935,170
Net Profit after Tax (2018-2019)	-	-	-	69,904,158	69,904,158
Revaluation Reserve Transfer	-	-	(3,467,051)	4,078,884	611,833
Cash dividend (2017-2018)	-	-	-	(39,855,233)	(39,855,233)
<b>Balance as at June 30, 2019</b>	<b>332,126,940</b>	<b>25,690,410</b>	<b>970,725,349</b>	<b>194,053,229</b>	<b>1,522,595,928</b>

For the year ended June 30, 2018

Particulars	Share Capital	Share Premium	Revaluation Reserve	Retained Earnings	Total
Balance as at July 01, 2017	332,126,940	25,690,410	977,892,094	126,428,238	1,462,137,682
Net Profit after Tax (2017-2018)	-	-	-	68,999,833	68,999,833
Revaluation Reserve Transfer	-	-	(3,699,694)	4,352,581	652,887
Cash dividend (2016-2017)	-	-	-	(39,855,233)	(39,855,233)
<b>Balance as at June 30, 2018</b>	<b>332,126,940</b>	<b>25,690,410</b>	<b>974,192,400</b>	<b>159,925,420</b>	<b>1,491,935,170</b>

  
Chairman

  
Managing Director

Signed in terms of our separate report of even date.

  
Company Secretary

Date: October 19, 2019  
Place: Dhaka

  
**FAMES & R**  
Chartered Accountants

**DELTA HOSPITAL LIMITED**  
**STATEMENT OF CASH FLOWS**  
For the year ended June 30, 2019

Particulars	Notes	Amount in Taka	
		30 -June - 19	30 -June - 18
<b>A. Cash flow from Operating Activities</b>			
Cash received from Customers and others	29.00	656,087,452	590,662,698
Cash paid to Suppliers	30.00	(194,412,024)	(174,981,319)
Cash Paid to Employees & others	31.00	(251,772,183)	(220,065,542)
Tax paid	31.00	(3,434,995)	(19,930,366)
<b>Net Cash flow from Operating Activities</b>		<b>206,468,250</b>	<b>175,685,471</b>
<b>B. Cash flow from Investing Activities</b>			
Acquisition of Property, Plant & Equipment		(31,622,920)	(36,963,745)
Capital Work-in process-Building		(62,966,614)	(72,764,675)
Stock of Furniture & Fixture		(775,681)	(27,771,441)
Stock of Machinery		(223,050,392)	-
Advances to construction Contractors		(115,909,132)	(157,640,453)
Rental Income		6,924,000	5,766,000
Bank Interest Received		4,856,688	8,448,563
<b>Net Cash used in Investing Activities</b>		<b>(422,544,051)</b>	<b>(280,925,751)</b>
<b>C. Cash flow from Financing Activities</b>			
Dividend Paid	32.00	(40,438,951)	(39,128,531)
Short Term Loan		50,354,167	30,276,452
Interest Paid		(105,404,881)	(69,356,893)
Long Term Loan -Term Loan		230,116,775	164,787,656
<b>Net Cash flow from Financing Activities</b>		<b>134,627,110</b>	<b>86,578,684</b>
<b>Net Increase / (Decrease) in Cash &amp; Cash Equivalent (A + B + C)</b>		<b>(81,448,691)</b>	<b>(18,661,596)</b>
Cash & Cash Equivalents at the Opening of the year		85,837,504	104,499,100
<b>Cash &amp; Cash Equivalents at the Closing of the year</b>		<b>4,388,813</b>	<b>85,837,504</b>
<b>Net Operating Cash Flows Per Share</b>		<b>6.22</b>	<b>5.29</b>

  
Chairman

  
Managing Director

Signed in terms of our separate report of even date.

  
Company Secretary

Date: October 19, 2019  
Place: Dhaka

  
**FAMES & R**  
Chartered Accountants



## **Delta Hospital Limited**

### **NOTES TO THE FINANCIAL STATEMENTS**

For the year ended June 30, 2019

#### **1.00 Material information of the entity**

##### **1.01 Legal form and country of incorporation**

Delta Hospital Limited formerly known as Delta Medical Centre Limited was incorporated with Registrar of Joint Stock Companies (RJSC) in Bangladesh on 4 June 1987 under the Companies Act, 1913 bearing registration no. C-16485(471)/87 as a Public Limited Company by shares. Subsequently, the Registrar of Joint Stock Companies has changed the name of the Company from Delta Medical Centre Limited to Delta Hospital Limited on 24 April 2007 under purview of the Companies Act 1994. Delta Hospital Limited submitted prospectus for raising TK. 50 Crore paid up capital by IPO that is now under process through Issue manager Prime Finance Capital Management Limited.

##### **1.02 Address of the Registered Office and Principal Place of business of the Company**

The company's registered Office and principal place of business is located at 26/2, Principal Abul Kashem Road (Former Darus Salam Road), Mirpur-1, Dhaka-1216

##### **1.03 Principal activities and nature of the business**

The main objective of the company are to set up and establish Medical College, Clinics, Hospitals, Dispensaries and extend facilities of investigation and treatment of the patients including Cancer, Medical, Surgical, Gynecology, Obstetrics, Pediatrics, Orthopedic etc.

#### **2.00 Significant Accounting Policies**

##### **Basis of Preparation of the Financial Statements**

The Financial Statements of the Company are prepared on a going concern Basis under historical cost convention and in accordance with the International Accounting Standards (IAS) and International Financial Reporting Standards (IFRS), the Companies Act 1994,

the Securities and Exchange Rules 1987 and other laws and rules applicable in Bangladesh.

##### **2.01 Investment in Globex Pharmaceuticals Limited**

Investment in Shares of Globex Pharmaceuticals Limited (GPL) has been shown at a cost of Tk. 34,316,517. The company was incorporated on 20th December 1992 with the Registrar of Joint Stock Companies having Certificate of Incorporation No :C-23228 (1633/92).

##### **2.02 Going Concern**

The company has adequate resources to continue in operation for the foreseeable future. For this reasons the directors continue to adopt going concern basis in preparing the financial statements. The current credit facilities and resources of the company provides sufficient fund to meet the present requirements of its existing business.

##### **2.03 Statement of Cash Flows**

Statement of Cash Flows is prepared in accordance with IAS 7 "Cash Flow Statement" and the Securities and Exchange Rules, 1987 and the cash flow from the operating activities are shown under the direct method as prescribed.

##### **2.04 Recognition of Property, Plant & Equipment and Depreciation**

###### **(i) Recognition and measurement**

###### **Freehold Assets**

The cost of an item of property and equipment is recognized as an asset if, it is probable that the future economic benefits associated with the item will flow to the company and the cost of item can be measured reliably.

Property, Plant and Equipment are stated at cost and revalued amount less accumulated depreciation. Cost represents the cost of acquisition includes purchase price and other directly attributable cost of bringing the assets

to working conditions for its intended use as per International Accounting Standard (IAS) 16 “Property, Plant and Equipment”.

#### (ii) Subsequent cost on Property and Equipment

Subsequent cost is capitalized only when it increases the future economic benefit from the assets and that cost can be measured reliably. All other expenditures are recognized as an expense as and when they are incurred.

#### (iii) Depreciation

Property, Plant & Equipment is stated at their cost and revalued amount less accumulated depreciation in accordance with IAS-16 “Property, Plant & Equipment”. Cost represents cost of acquisition or construction. No depreciation is charged on Land and Land Development. Depreciation has been charged on addition of fixed assets when it is available for use. Depreciation on all fixed assets has been applied at the following rate.

SL No	Particulars	Depreciation Charge
1	Land	0%
2	Land Developments	0%
3	Building & Construction	5.50%
4	Furniture and Fixture	15%
5	Electricity and Sanitary Fittings	20%
6	Machinery and Equipments	10%
7	Surgical Equipments	12%
8	Electrical Equipments	15%
9	Office Equipments	20%
10	Motor Vehicles	15%
11	Wasa line installation	20%

Current year’s depreciation has been charged on reducing balance method consistently with that of previous year and the cost and accumulated depreciation of assets retired or otherwise disposed off are subject to elimination from the assets and accumulated depreciation and any gain or loss arising on the disposal or retirement of an asset is determined as the difference between the sale proceeds and the carrying amount of the asset and is recognized in the statement of Profit or Loss and other Comprehensive Income.

## 2.05 Impairment

In accordance with the provisions of IAS-36, the carrying amount of non-financial assets other than inventories of the company involved in the manufacturing of the products. If any such indication exists, then the asset’s recoverable amount is estimated and impairment losses are recognized in profit or loss account. No such indication of impairment has been observed till the end of the year.

## 2.06 Revenue Recognition

Revenue is recognized only when it is probable that the economic benefit of such transaction has been derived as per IFRS-15 “Revenue from Contracts with Customers”.

Service revenue is recognized when transactions related to services is completed and the service invoices are issued in favor of the patients.

## 2.07 Value Added Tax (VAT):

The company’s service income is exempted from VAT by a Court Order dated July 15, 2009. As such as VAT liabilities are required to account for as per VAT Act 1991.

## 2.08 Financial Instruments

### Derivative

According to IFRS-7: “Financial Instruments: Disclosures”, the company was not a party to any derivative contract (financial instruments) at the Financial Statements date, such as forward exchange contracts, currency swap agreement or contract to hedge currency exposure related to import of capital machinery to be leased to lessees in future.

### Non-Derivative

A non-derivative financial instrument comprises of accounts and other receivable, borrowings and other payables is shown at transaction cost as per IAS 39 “Financial Instruments: Recognition and Measurement”.

### Accounts Receivable

These are carried forward at their original invoiced value amount and represents net

realizable value. Management considered the entire bills receivable as good and is collectable and therefore, no amount was provided for as bad debt in the current year's account.

### Stock and Stores

In compliance with the requirements of IAS 2 "Inventories", the Inventories have been valued at the lower of cost and net realizable value at weighted average method, which is consistent in line with the previous year's practice.

### Creditors and Accrued Expenses

Liabilities are recognized as amounts to be paid in future for goods and services received, whether or not billed by the supplier.

## 2.09 Cash & Cash Equivalent

It includes Cash in hand and Cash at bank which were held and available for use by the company without any restriction and there was insignificant risk of change in value of these current assets.

## 2.10 Currency of Reporting and Foreign Currency Transactions

### Currency of Reporting:

The financial statement of the Company has been prepared in Taka (BDT).

### Foreign Currency Transactions

Foreign Currency Transactions in foreign currencies are converted into equivalent Taka applying the ruling rate at the date of such transactions as per IAS-21 "The Effects of Changes in Foreign Exchange Rates" and Gain or Loss on Transaction in recognition.

## 2.11 Long Term Liabilities

Long term liabilities comprises the amount borrowed from the bank and other concern for the long period of time and accounted and shown in the accounts at transaction cost as per IAS 39 "Financial Instruments: Recognition and Measurement".

## 2.12 Contingent Liabilities

Contingent Liabilities are those which arise due to the past event which shall be settled in the

future on the occurrence or non occurrence of some uncertain event, cost of which can be measured reliably as per IAS-37 "Provision and Contingent Assets and Liabilities". Contingent Liabilities are fully disclosed in Note-36.

## 2.13 Revaluation Reserve

A number of fixed assets were revalued by the company as on June 30, 2010 which was conducted by a professional valuer M/S GK Adjusters Ltd. In order to reflect the fair picture of the company in the present market condition on the Basis of market availability and physical condition of those fixed assets and the gain arises due to the revaluation were transferred to the revaluation reserve account as per IAS 16 "Property, Plant and Equipment".

## 2.14 Taxation

### Current Tax

Provision for current Income Tax has been made at the rate of 35% as prescribed in the Finance Act, 2019 on the accounting profit made by the Company making some adjustments as per ITO 1984 in compliance with IAS-12 "Income Taxes".

### Deferred taxation

Deferred tax liabilities are the amount of income taxes payable in future years in respect of taxable temporary differences. Deferred tax assets are the amount of income taxes recoverable in future years in respect of deductible temporary differences. Deferred tax assets and liabilities are recognized for the future tax consequences of timing differences arising between the carrying values of assets, liabilities, income and expenditure and their respective tax IAS. Deferred tax assets and liabilities are measured using tax rates and tax laws that have been enacted or subsequently enacted at the balance sheet date. The impact on the account of changes in the deferred tax assets and liabilities for the year ended June 30, 2019 has been recognized in the statement of Profit or loss and other comprehensive income as per IAS-12 "Income Taxes".

## 2.15 Benefit to the employees

Delta Hospital Ltd. offers a number of benefit plan for all permanent Employee's of the company which includes Contributory Provident Fund, Gratuity Fund, WPPF and Group Insurance Policy which have been accounted for in accordance with the provision of International Accounting Standard (IAS) -19, "Employee Benefit" Basis of enumeration the above benefits schemes operated by the company are outlined below:

### a. Defined Contribution Plan

The Company operates a contributory provident fund for all of its permanent employees. The fund is approved by the National Board of Revenue (NBR) 1AA Provi-01/2011-12/381 Dated: 18.09.2011 administered separately by a Board of Trustees and is funded by the equal contribution both by the Company and employees at a predetermined rate.

### b. Defined benefit plan (Gratuity scheme)

The Company has an unfunded gratuity scheme for all eligible employees who have completed minimum 05 (five) years of confirmed service with the Company. Required amount of gratuity is calculated on the Basis of last Basic pay depending on the length of service for every completed year as well as proportionate to the fraction period of service as of the respective financial year.

### c. Group Insurance

The company has been operating a Group Insurance policy for all Permanent employees for the supporting of family assistance after death of any Employee's as per terms & condition of Group Insurance Policy.

### d. Workers Profit Participation Fund (WPPF)

The Company is operating Workers Profit Participation Fund (WPPF) according to International Labour Law 2006. The company pays to the Participation fund, the welfare fund and fund established under section 14 of International Workers Welfare Foundation Act, 2006. Benefit has given not later than six

months from the close of that year, five percent (5%) of its profits during such year. The proportion of the Payment to abovementioned funds shall be 80:10:10 respectively.

## 2.16 Borrowing Costs

The borrowing costs were capitalized unless active development of related assets were interrupted or cease when the borrowing cost directly transferred to the Statement of Profit or Loss and other comprehensive income as per IAS-23 "Borrowing Costs".

## 2.17 Earnings Per Share (EPS)

The company calculates Earning per Share (EPS) in accordance with IAS-33 "Earnings per Share" which has been shown on the face of the Statement of Profit or Loss and Other Comprehensive Income. Categories of EPS are as follows:

### Basic earnings per share

This represents earnings for the year attributable to ordinary shareholders. As there was no preference dividend, minority interest or extra ordinary items, the net profit after tax for the year has been considered as fully attributable to the ordinary shareholders.

### Weighted average number of ordinary shares outstanding during the year

This represents the number of ordinary shares outstanding at the beginning of the year plus the number of shares issued during the year multiplied by a time-weighted factor is the number of months the specific shares is outstanding as a proportion of the total number of months in the year.

### Diluted earnings per share

No diluted earnings per share are required to be calculated for the year as there was no scope for dilution during the year under review.

## 2.18 Information about business segments

As per IFRS 8 "Operating Segment" is a distinguishable component of a company that is engaged in providing an individual product or service or a group of related product or service



and that is subject to risk and return that are different from those of other business segment. During the year under review the company had no operational segment either business or geographical segments.

### 2.19 Events after the Reporting date

As per IAS-10 “Event after the Reporting Period” are those event favorable and unfavorable, that occur between the end of the reporting year and the date when the financial statements are authorized for issue. Two types of event can be identified:

- those that provide evidence of conditions that existed at the end of the reporting year (adjusting events after balance sheet date); and
- Those that are indicative of conditions that arose after the reporting year (Non-adjusting events after balance sheet date).

The Board of Directors has proposed 12% Cash dividend on the paid up capital of the company which is to be confirmed in the next Annual General Meeting (AGM) of the shareholders.

### 2.20 Related Parties Transactions

The party is related to the company if the party has significant influence over the subject matters and also holding the controlling power of the management affairs of the company and any transaction made during the year with the party related therewith is termed as related party transaction as per IAS-24 "Related Party Disclosures". During the year under audit there is no such related party transactions made that has influenced the company's business. Related parties are fully disclosed in Note-34.

### 2.21 Risk Perception

There are some internal and external factors that may conceivably materially affect the company's operation of business. The Company Management perceives investment risk within the national and international economic perspectives in relation to legal, financial, economic and moral requirements involving inter alia, foreign currency fluctuation, interest rate risk, scientific invention, monetary and

fiscal investment policies and has prepared its financial and marketing strategies to meet the challenges from these risks.

### 2.22 Application of International Accounting Standards (IASs)

The Financial statements have been prepared in compliance with requirement of IAS as adopted by The Institute of Chartered Accountants of Bangladesh (ICAB). The following IASs are applicable for the financial statements for the period under review:

IAS-1	Presentation of Financial Statements
IAS-2	Inventories
IAS-7	Statement of Cash Flows
IAS-8	Accounting Policies, Changes in Accounting Estimates and Errors
IAS-10	Events after the Reporting Period
IAS-12	Income Taxes
IAS-16	Property, Plant & Equipment
IAS-19	Employees Benefit
IAS-23	Borrowing Cost
IAS-24	Related Party Disclosures
IAS-32	Financial Instruments Presentation
IAS-33	Earnings Per Share (EPS)
IAS-36	Impairment of Assets
IAS-37	Provisions, Contingent Liabilities and Contingent Assets
IAS-39	Financial Instruments : Recognition and Measurement
IFRS-7	Financial Instruments : Disclosures
IFRS-9	Financial Instruments
IFRS-13	Fair Value Measurement
IFRS-15	Revenue from Contracts with Customers

### 2.23 Additional Information on Financial Statement Responsibility for preparation and presentation of financial statements

The company's management and the Board of Directors are responsible for the preparation and presentation of Financial Statements as per section 183 of the companies Act 1994

**Components of the Financial Statements**

Following are the component of the financial statements for the year ended June 30, 2019.

- a) Statement of Financial Position;
- b) Statement of Profit or Loss and Other Comprehensive Income;
- c) Statement of Cash Flows;
- d) Statement of Changes in Equity and
- e) Explanatory notes to the financial statements.

**Uncertainties for use of estimates in preparation of financial statements**

The preparation of financial statements in conformity with the International Accounting Standards requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of other information at the date of the financial statements and revenues and expenses during the year reported. Actual results could differ from those estimates. Estimates are used for accounting of certain items such as depreciation on fixed assets, accrued expenses and income taxes.

**Compliance with Local Laws**

The financial Statements have been prepared in compliance with requirements of the companies Act 1994 and other relevant local laws and rules.

**Comparative**

Comparative information have been disclosed in respect of the previous year for all numerical information in the financial statements and also the narrative and descriptive information when it is relevant for understanding of the current year's financial statements.

**Re-arrangement**

Previous year's figures have been re-arranged and applied retrospective restatement whenever necessary to ensure comparability with the current year's presentation.

**Reporting Currency**

The figure has been rounded off to the nearest Taka except where indicated otherwise.

**Date of Authorization**

The Board of Directors accorded its approval and authorized these financial statements on October 19, 2019.

**Reporting Period**

The financial Statement has been prepared covering the period from July 01, 2018 to June 30, 2019.

**2.24 Financial Risks**

The Hospital's activities are exposed to in a range of financial risks. These risks include Market risk including Foreign Currency risk, Interest rate risk, Credit risk, and liquidity risk.

**Market risk**

Market risk is the risk that encompasses a variety of financial risks, such as foreign currency risk, interest rate risk and saleable product price risk. Significant volatility in interest rates, equity values will affect Company's income or the value of its holdings of financial instruments. The objective of market risk the management is to manage and control market risk exposures within acceptable parameters, while optimizing the return.

**(i) Foreign currency risk**

Foreign currency exposure arises from purchases and other transactions which denominated in foreign currencies.

**(ii) Interest rate risk**

Interest rate risk refers to the effect on the fair value or future cash flows of a financial instrument due to fluctuations in interest rates. The entities interest bearing investments are exposed to interest rate risk. The most significant exposure to interest rate risk is the Hospital's Borrowing long term and short term loan from NCC Bank Ltd.

Duration measures the sensitivity of the price of financial instruments for every 1% change in Interest rates.



**Credit risk**

Credit risk on financial instruments is the risk of financial loss occurring as a result of default or insolvency of counterparty on its obligations to repay to the Hospitals and arises principally from the receivable from customers and other parties.

**Liquidity risk**

Liquidity risk is the Company will not be able to meet its financial obligations as they fall due. The company's approach to managing liquidity is to ensure, as far as possible that it will always have sufficient liquidity to meet its liabilities when due, under both normal and

stressed conditions without incurring unacceptable losses or risking damage to the company's reputation. Typically the Company ensures that it has sufficient cash and cash equivalents to meet expected Operational expenses, including financial obligations through preparation of cash flow forecast , prepared based on time line of payment of the financial obligations and accordingly arrange for sufficient liquidity/fund to make the expected payment within due date.

As at 30 June 2019, the Company had adequate cash to meet its financial obligations and liquidity risk is considered insignificant.

**3.00 Property, Plant & Equipment**

**a) Cost**

Opening balance at cost  
Add : Addition during the year  
Total

**Depreciation**

Opening balance  
Add: Charged during the year

**Total ( a)**

**Revaluation**

Opening balance  
Total

**b) Depreciation**

Opening balance  
Add: Charged during the year

**Total (b)**

**Written Down Value (WDV) (a+b)**

Details have been shown in annexure -A

**4.00 Capital Work in Process-Building**

Opening Balance  
Add: Addition during the Year  
Add: Interest during the Year

Less: Amount Transferred to PPE

As a part of business development the company management undertook a massive construction of a new Ten storied Hospital building in its own land. The work in Process represents the on going construction cost of the hospital building which includes an amount of Tk. 52,928,890 paid to NCC Bank Limited as interest expenses for Term loan for construction of the said hospital Building. As per IAS - 23 "Borrowing Costs" these interest would be capitalized as PPE under the head Building construction .

**4.01 Stock of Furniture & Fixture**

Opening Balance  
Add: Addition during the Year

Less: Amount Transferred to PPE

**4.02 Stock of Machinery**

Opening Balance  
Add: Addition during the Year  
Add: Interest during the Year

Less: Amount Transferred to PPE

Amount in Taka	
30-June- 2019	30-June- 2018
1,367,923,684	1,164,196,394
251,738,920	203,727,290
<b>1,619,662,604</b>	<b>1,367,923,684</b>
400,337,002	331,149,437
75,711,505	69,187,565
<b>476,048,507</b>	<b>400,337,002</b>
<b>1,143,614,097</b>	<b>967,586,682</b>
1,054,679,378	1,054,679,378
<b>1,054,679,378</b>	<b>1,054,679,378</b>
31,897,884	27,545,302
4,078,884	4,352,581
<b>35,976,768</b>	<b>31,897,884</b>
<b>1,018,702,610</b>	<b>1,022,781,494</b>
<b>2,162,316,707</b>	<b>1,990,368,177</b>

172,731,848	166,138,909
220,607,067	137,681,684
52,928,890	35,674,800
<b>446,267,805</b>	<b>339,495,393</b>
(220,116,000)	(166,763,545)
<b>226,151,805</b>	<b>172,731,848</b>

27,771,441	-
775,681	27,771,441
<b>28,547,122</b>	<b>27,771,441</b>
-	-
<b>28,547,122</b>	<b>27,771,441</b>

-	-
223,050,392	-
5,503,781	-
<b>228,554,173</b>	-
-	-
<b>228,554,173</b>	-

**5.00 Inventories**

Medicine
Materials for Pathology
Materials for X-Ray
General Store Stock
Printing & Stationery Materials
Materials for Electrical Maintenance

Amount in Taka	
30-June- 2019	30-June- 2018
17,506,277	15,269,047
7,308,841	6,974,525
207,256	232,479
9,794,301	9,031,481
498,025	486,281
125,328	132,996
<b>35,440,028</b>	<b>32,126,809</b>

**6.00 Trade and Other Receivable**

Receivable from Patient Bill
Receivable from Various Corporate Party
Accrued Interest FDR
ATM, Brac Bank
Delta Hospital Canteen Rent
Accrued Interest (Globex Pharma)
Income Tax Refundable (Note: 6.01)

6,516,645	8,042,283
7,271,932	8,533,636
-	943,013
-	45,600
1,200,000	-
4,210,475	3,010,475
11,512,730	-
<b>30,711,782</b>	<b>20,575,007</b>

**6.01 Income Tax Refundable**

Opening Balance
Added during the Period

-	-
11,512,730	-
<b>11,512,730</b>	<b>-</b>
-	-
<b>11,512,730</b>	<b>-</b>

Adjusted during the Period
Closing Balance

**Tk. 11,512,730** is refundable Income tax from the year 2017-2018 as the demand note issued by the Income tax authority.

**6.02 Disclosure as per Schedule-XI, Part -I, of The Companies Act, 1994**

Maturity less than 6 months
Maturity more than 6 months
<b>Total</b>

14,988,577	17,564,532
15,723,205	3,010,475
<b>30,711,782</b>	<b>20,575,007</b>

Debts considered Good without security

<b>30,711,782</b>	<b>20,575,007</b>
-------------------	-------------------

**7.00 Advances, Deposits & Prepayments**

Advance to Employee and Staff
Security Deposits (T & T, DESA, WASA & TITAS)
Advance for IPO Expenses
Advanced to DESCO
Advanced to Shariful Islam (Optimal IT)
Advanced to Shafiqul Islam (Pharmacy Incharge)
Advances To Others
Advance bill(Purchase)
Advances for Construction
Advance to Trade Concern
Advanced to Michael Corporation Int.
Advanced to Electro Mart Ltd
Advance to Bengal Tech ( Fire Protection)
Advanced to Ardib Ent.
Advanced to Inter Link Technology Ltd
Advanced to Technoworth Associates
Advanced to Barger Paint
Advanced to Shameem Refregeration
Advanced to Credible Technology
Advanced to Adex Corporation
Advanced to Ferrous Buildings Ltd

3,106,000	3,806,016
3,157,280	1,157,280
6,360,879	6,360,879
-	1,980,017
75,000	75,000
100,000	100,000
-	76,692
52	89,277
113,408,802	146,722,997
-	469,200
-	253,266
-	825,855
960,000	1,758,255
-	350,000
-	249,000
-	1,200,000
-	172,000
-	646,980
-	60,900
-	4,250,000
-	625,000

Advanced to Sigma Pumps Ltd  
Advance To M/S Trisha Timber Traders  
Advance to Navana Furniture Ltd.  
Advance to Dexterous Consultant Ltd.  
Advance to Celltech Architect & Engineers  
Advance to Group Tex  
Advance To Precision Medical Resources  
Advance Income Tax ( Note:7.01)

Amount in Taka	
30-June- 2019	30-June- 2018
-	57,000
100,000	-
120,330	-
500,000	-
100,000	-
300,000	-
420,000	-
23,365,361	43,822,045
<b>152,073,704</b>	<b>215,107,659</b>

**7.01 Break-up of advance income tax**

Assessment Year 2017-18 Vehicle tax  
Assessment Year 2018-19 Vehicle tax  
Advance Vehicle Tax Asst. Year-2019-20  
Assessment Year 2017-18 Rental Income  
Assessment Year 2018-19 Rental Income  
Assessment Year 2019-20 Rental Income  
Assessment Year 2017-18 Bank interest  
Assessment Year 2018-19 Bank interest  
Advance Tax Bank Interest Asst Year-2019-20  
Assessment Year 2017-18 Corporate tax  
Assessment Year 2018-19 Corporate tax  
Advance Corporate Tax Asst. Year-2019-20

-	149,000
145,000	145,000
165,000	-
-	34,875
40,800	38,800
290,320	-
-	728,207
746,566	746,566
477,675	-
-	22,979,597
19,000,000	19,000,000
2,500,000	-
<b>23,365,361</b>	<b>43,822,045</b>

**7.02 Disclosure as per Schedule-XI, Part -I, of The Companies Act, 1994**

Advance not exceeding 6 months  
Advance exceeding 6 months

119,015,184	211,795,362
33,058,520	3,312,297
<b>152,073,704</b>	<b>215,107,659</b>

Advance, deposits & prepayments considered good & secured  
Advance, deposit & prepayments considered good without security  
Advance, deposit & prepayments considered doubtful & bad  
Advance, deposit & prepayments due by directors or other officers & staffs  
Advance, deposit & prepayments due from companies under same management  
Maximum advance due by directors or officers & staffs at any time

148,967,704	211,301,643
-	-
-	-
3,106,000	3,806,016
-	-
-	-

**8.00 Loan to Globex Pharmaceuticals Ltd.**

The balance of the company Tk. 10,000,000 has been carried from the last few years without of any changes.  
The management of the company has taken initiative to collect the above amount in the upcoming financial year. The Board has approved 12% Interest on the amount and accounted for the interest by following IAS-24 and Companies Act 1994 accordingly.

**9.00 Investment in share-Globex Pharmaceuticals Ltd.**

Globex Pharma Ltd.

34,316,517	34,316,517
<b>34,316,517</b>	<b>34,316,517</b>

Investment in Shares of Globex Pharmaceuticals Ltd. represent Tk. 34,316,517 as at 30.06.2019. The company was incorporated on 20 the December 1992 with the Registrar of Joint Stock Companies & Firms having issuance of Certificate of Incorporation No :C-23228 (1633/92) on that date.

**10.00 Cash & Cash Equivalents**

Cash in hand	
Cash at bank	
BRAC Bank STD A/C-1501100131993001	
BRAC Bank CA A/C-1501200131993001	
NCC Bank SND-205	
Dhaka Bank Dhanmondi STD A/C - 205.150.58	
Dutch Bangla Bank STD A/C -115.120.442	
Basic Bank Savings A/C-19798	
Basic Bank STD A/C-806	
Basic Bank A/C-10881	
SBAC Bank A/c. 20231	
SBAC Bank A/c. 27589	
FDR's	(Note-10.01)

Amount in Taka	
30-June- 2019	30-June- 2018
2,595,966	2,536,301
<b>1,792,847</b>	<b>83,301,203</b>
13,049	13,049
119,852	885,997
53,390	257,462
5,898	7,220
1,378,723	2,417,906
10,809	10,649
8,678	7,692
1,354	5,004
193,864	1,733
7,230	8,645
-	79,685,846
<b>4,388,813</b>	<b>85,837,504</b>

**10.01 FDR's**

Opening balance	
Addition made during the year	

Less: Encashment made during the year	
Closing balance	

79,685,846	101,951,653
12,029,053	156,090,005
91,714,899	258,041,658
(91,714,899)	(178,355,812)
-	<b>79,685,846</b>

FDR No.	Bank	Branch	Amount In Taka 30.06.2019
0033242002329	SBAC Bank Ltd	Mirpur branch	-
0033242002294	SBAC Bank Ltd	Mirpur branch	-
0033242002310	SBAC Bank Ltd	Mirpur branch	-
0033242002301	SBAC Bank Ltd	Mirpur branch	-
0033242005915	NCC Bank Ltd	Darussalam Road branch	-
0033242008106	NCC Bank Ltd	Darussalam Road branch	-
			-

**11.00 Share Capital**
**Authorized Capital**

100,000,000 Ordinary Shares @ Tk. 10 each

1,000,000,000 1,000,000,000

**Issued, Subscribed & Paid up Capital**

33,212,694 Ordinary Shares @ Tk. 10 each fully paid-up in Cash

332,126,940 332,126,940

**Total Paid Up Capital**
**332,126,940 332,126,940**
**Particulars of share holders and their share holding position is as under**

Sl. No	Name of Shareholders	Number of Shares	
		30-Jun-19	30-Jun-18
1	Mr. Mir Amjad Hussain	1,045,492	1,045,492
2	Dr. Syed Mukarram Ali	1,305,000	1,305,000
3	Mr. A.Q.M. Nurul Absar	1,423,942	1,423,942
4	Mr. Habibur Rahman	1,000,001	1,000,001
5	Mrs. Nazmin Showkat Ali	1,814,579	1,814,579
6	Mr. Mohd. Shawkat Ali	1,069,511	1,069,511
7	Mr. Mahmud Hassan	1,010,000	1,010,000
8	Mr. Nurul Huda	1,453,028	1,453,028
9	Mr. Abu Saleh Abdul Muiz	1,069,511	1,069,511
10	Mr. Md. Obaidur Rahman	1,829,527	1,829,527
11	Mr. Mizanur Rahman Sarker	1,002,665	1,002,665
12	Other Shareholders	19,189,438	19,189,438
<b>Total</b>		<b>33,212,694</b>	<b>33,212,694</b>

**Classification of shares by holding**

Slabs by Number of Shares	No. of Shareholders	No. of Shares
Less Than 500	6	853
From 501 to 5,000	14	38,479
From 5,001 to 10,000	23	170,537
From 10,001 to 20,000	27	371,819
From 20,001 to 30,000	35	888,545
From 30,001 to 40,000	22	781,303
From 40,001 to 50,000	5	225,498
From 50,001 to 1,00,000	37	2,462,677
From 1,00,001 to 10,00,000	48	12,072,115
Above 10,00,000	13	16,200,868
<b>Total</b>	<b>230</b>	<b>33,212,694</b>

**12.00 Share Premium**

Issued 17,12,694 Right Shares each @ Tk. 15 as Premium

Amount in Taka	
30-June- 2019	30-June- 2018
25,690,410	25,690,410
<b>25,690,410</b>	<b>25,690,410</b>

**13.00 Retained Earnings**

Opening Balance

Add : Profit after Tax during the Year

Add : Transferred from revaluation reserve

Less : Dividend paid for 2017-2018

Retained Earnings Balance as at June 30, 2019

159,925,420	126,428,238
69,904,158	68,999,833
<b>229,829,578</b>	<b>195,428,071</b>
4,078,884	4,352,581
<b>233,908,462</b>	<b>199,780,653</b>
39,855,233	39,855,233
<b>194,053,229</b>	<b>159,925,420</b>

**14.00 Revaluation Reserve**

Opening Balance

Less: Transfer to Retained Earnings

Add: Related Tax & Adjustment

974,192,400	977,892,094
(4,078,884)	(4,352,581)
611,833	652,887
<b>970,725,349</b>	<b>974,192,400</b>

Fixed assets were revalued by the company as on June 30, 2010 which was conducted by a professional valuer GK Adjusters Ltd. In order to reflect the fair picture of the company in the present market condition on the basis of market availability and physical condition of those fixed assets and the gain arises due to the revaluation were transferred to the revaluation reserve account as per IAS 16 "Property, Plant and Equipment".

**15.00 Long Term Borrowing /Loan**

Opening Balance

Add: Received/Transferred during the year

Add: Profit /Interest for the year

Less: Paid during the year

Principal

Interest

**Closing Balance**

Less: Current Maturity

**Balance after current maturity**

724,405,048	559,617,393
303,798,891	860,411,963
94,088,527	64,405,561
1,122,292,466	1,484,434,917
(73,682,116)	(695,624,308)
(94,088,527)	(64,405,561)
<b>954,521,823</b>	<b>724,405,048</b>
(199,967,088)	(165,093,072)
<b>754,554,735</b>	<b>559,311,976</b>

1) Bank : NCC Bank Ltd.	2) Bank : NCC Bank Ltd.	3) Bank : NCC Bank Ltd.
Sanction Limit : Tk. 847,000,000	Sanction Limit : Tk.157,600,000	Sanction Limit : Tk. 110,000,000
Sanction Date: December 04, 2017	Sanction Date: January 01, 2019	Sanction Date: February 25, 2019
Rate of Interest / Profit : @ 9%	Rate of Interest / Profit: @ 12%	Rate of Interest / Profit : @ 12%
Security : Land, Building & Machineries	Security: Land, Building & Machineries	Security : Land , Building & Machineries



**16.00 Deferred Tax**

**Deferred tax liabilities**

As at 30 June 2019	Carrying amount	Tax base	Taxable/ deductible temporary difference
Property, plant & equipments except land at cost	1,126,184,881	810,294,554	315,890,327
Revaluation surplus on Land	952,982,983	-	952,982,983
Revaluation surplus-PPE	65,719,628		65,719,628
<b>Total taxable temporary difference</b>	<b>2,144,887,492</b>	<b>810,294,554</b>	<b>1,334,592,938</b>
Tax on business income			35%
Tax on Land			4%
Tax on capital gain			15%
Closing deferred tax liabilities/(assets)-at cost			110,561,614
Closing deferred tax liabilities/(assets)-at revaluation			47,977,264
<b>Total closing deferred tax liabilities/(assets)</b>			<b>158,538,878</b>
Opening deferred tax liabilities/(assets)-at cost			95,820,005
Opening deferred tax liabilities/(assets)-at revaluation			48,589,096
<b>Total opening deferred tax liabilities/(assets)</b>			<b>144,409,101</b>
Deferred tax expense/(income)-at cost			14,741,610
Deferred tax expense/(income)-at revaluation			(611,833)
<b>Total deferred tax expense/(income)</b>			<b>14,129,777</b>

**Deferred tax liabilities**

As at 30 June 2018	Carrying amount	Tax base	Taxable/deductible temporary difference
Property, plant & equipments except land at cost	950,157,466	676,386,024	273,771,442
Revaluation surplus on Land	952,982,983	-	952,982,983
Revaluation surplus-PPE	69,798,512		69,798,512
<b>Total taxable temporary difference</b>	<b>1,972,938,961</b>	<b>676,386,024</b>	<b>1,296,552,937</b>
Tax on business income			35%
Tax on Land			4%
Tax on capital gain			15%
Closing deferred tax liabilities/(assets)-at cost			95,820,005
Closing deferred tax liabilities/(assets)-at revaluation			48,589,096
<b>Total closing deferred tax liabilities/(assets)</b>			<b>144,409,101</b>
Opening deferred tax liabilities/(assets)-at cost			83,103,355
Opening deferred tax liabilities/(assets)-at revaluation			49,241,983
<b>Total opening deferred tax liabilities/(assets)</b>			<b>132,345,339</b>
Deferred tax expense/(income)-at cost			12,716,649
Deferred tax expense/(income)-at revaluation			(652,887)
<b>Total deferred tax expense/(income)</b>			<b>12,063,762</b>

**Deferred tax liabilities**

**17.00 Short Term Bank Loan**

Name of the Bank:

Overdraft NCC Bank A/C 136 (Note: 17.01)

Overdraft(FO) NCC Bank A/C 601

Loan From WPPF Fund

Loan From Delta Medical College

LATR

**Total**

116,658,470 79,953,362

- 1,095,307

2,148,500 -

7,579,861 -

10,073,492 5,057,487

**136,460,323 86,106,156**

**17.01** Above amount has been sanctioned of Tk. 120,000,000. Sanction Date February 25, 2019. Rate of Interest / Profit: @ 12.00%. Security: Inventory.

**18.00 Accrued Expenses / Provision & Accruals**

Amount in Taka		
	30-June- 2019	30-June- 2018
Salary and Allowances	10,748,791	10,293,542
Wasa Bill	97,583	125,351
Gas	13,324	6,000
Electric Bill	1,986,999	-
Telephone Bills	39,743	30,000
Audit Fees	200,000	200,000
Group Insurance Premium Payable	285,940	-
Retention Money	27,148,206	27,632,673
Consultancy Fees	1,489,730	1,155,320
With Holdings Tax	3,526,044	2,236,905
With Holdings VAT	554,050	870,777
Lucky Bakery	-	152,088
Patient bill advance	2,208,161	2,694,443
Pass Card	109,995	97,230
WPPF & Welfare Fund (Note: 18.01)	4,712,685	5,391,678
<b>Total</b>	<b>53,121,250</b>	<b>50,886,006</b>

**18.01 WPPF & Welfare Fund**

Opening Balance	5,391,678	<b>5,321,598</b>
Add: During the year	4,741,489	5,420,482
	<b>10,133,167</b>	<b>10,742,079</b>
Less: Paid during the year	(5,420,482)	(5,350,401)
	<b>4,712,685</b>	<b>5,391,678</b>

The company considered and operating WPPF @ 5% on it's profit according to Bangladesh Labour Law 2006.(Ammendment-2013).

**19.00 Accounts Payable**

Opening balance	32,422,294	32,892,544
<b>Add:</b> Addition/Adjustment during the year	383,431,501	365,982,312
	415,853,795	398,874,856
<b>Less:</b> Paid During the year	386,332,453	366,452,562
	<b>29,521,342</b>	<b>32,422,294</b>

There is no related party transaction.

**20.00 Provision for Current Tax**
**Current Tax**

Opening Balance	48,764,516	45,690,623
Add : Provision made during the year ( Note:20.01)	10,184,004	26,693,151
	58,948,520	72,383,774
Less : Adjustment for the AY-2017-18	12,378,949	23,619,258
<b>Closing Balance</b>	<b>46,569,571</b>	<b>48,764,516</b>

Assessment of the Income Tax upto the Assessment year 2017-2018 has been completed. But assessment for the AY 2018-19 is under process. Therefore, adjustment of the income tax did not made in the financial statements during the year 2019.

**20.01 Current Tax**

Profit Before Tax	94,829,772	108,409,633
Add: Accounting Depreciation	79,790,389	73,540,147
Less: Tax Depreciation	(117,830,390)	(105,683,635)
Taxable Income for the year	<b>56,789,771</b>	<b>76,266,144</b>
Rate of Tax	35%	35%
Tax on business	19,876,420	26,693,151
Less: Excess Provision Adjustment	(9,692,416)	-
<b>Total Provision for the year</b>	<b>10,184,004</b>	<b>26,693,151</b>

		Amount in Taka	
		30-June- 2019	30-June- 2018
<b>21.00</b>	<b>Other Liabilities</b>		
	Contributory provident Fund	4,000,710	2,152,127
	Unclaimed Dividend (Note: 21.01)	7,170,826	7,754,544
	<b>Total</b>	<b>11,171,536</b>	<b>9,906,671</b>
<b>21.01</b>	<b>Unclaimed Dividend</b>		
	Opening balance	7,754,544	7,027,842
	Add: Cash Dividend paid during the year	39,855,233	39,855,233
		47,609,777	46,883,075
	Less: Collected by the shareholders during the year	40,438,951	39,128,531
	<b>Closing balance</b>	<b>7,170,826</b>	<b>7,754,544</b>

		Amount in Taka	
		30-June-2019	30-June-2018
<b>22.00</b>	<b>Revenue</b>		
	Seat Rent	76,528,811	66,100,926
	Pathology	111,175,379	83,970,065
	OT, POC, Labour Charges	8,296,520	6,681,963
	Ultra sonogram	11,131,642	8,917,787
	Endoscopy	1,693,220	1,784,196
	X-ray ECG & OPD	12,101,259	7,744,881
	ECHO	3,185,930	2,633,325
	Laparoscopy	174,600	118,000
	Ambulance Services	1,506,338	1,115,684
	Oxygen	2,896,742	2,608,095
	Medicine & Vaccination	184,988,744	153,603,281
	Cesarean items sales	5,005,644	3,357,078
	Misc. Income	636,902	1,441,576
	Radiotherapy	39,197,926	52,980,839
	LINAC Therapy	96,692,387	78,355,914
	Memography	503,510	466,213
	Physiotherapy Income	1,586,030	1,779,440
	ICU	18,623,358	19,909,565
	PCU	3,233,263	2,919,688
	Planning	25,765,680	42,056,697
	Professional Fees / Registration	14,731,371	13,566,085
	Chemotherapy	17,739,379	17,123,602
	Brachy Therapy	5,111,354	14,040,677
	E.N.T. Examination-R	849,660	-
	Skin Examination Fee-R	130,200	-
	Eye-Examination-R	38,900	-
	URO Examinaton-R	11,450	-
	CT SCAN	9,763,911	8,966,585
	<b>Total</b>	<b>653,300,110</b>	<b>592,242,162</b>
<b>23.00</b>	<b>Operating / Direct Expenses</b>		
	Salary and Allowances	124,779,310	101,172,056
	Consultant Fees	4,550,975	4,353,310
	Oxygen & Misc. Purchases	27,917,056	25,728,519
	Cost of Medicine Sold	153,243,885	140,529,677
	Pathology / X-Ray	6,785,210	5,512,350
	Physiotherapy Expenses	251,702	179,180
	Depreciation	79,790,389	73,540,147
		<b>397,318,527</b>	<b>351,015,239</b>
<b>24.00</b>	<b>General and Administrative Expenses</b>		
	Salary and Allowances	65,528,829	55,391,309
	Printing	816,550	672,333
	Postage (Courier Services)	523,619	536,780
	Stationery	2,928,665	2,827,300
	Publication	517,416	530,873
	Telephone	165,369	166,680
	Motor Vehicle Fuel	2,074,325	2,013,643
	Motor Vehicle Maintenance	1,234,328	1,108,884
	Utilities Expenses	17,888,168	15,734,131
	Generator Fuel and Oil	4,346,577	4,177,693
	Patients Food Supplies	5,358,192	4,451,979
	Conveyance	2,038,912	2,456,107
	Entertainment	590,569	512,595
	Insurance	690,798	757,780
	Professional Fees	285,000	306,907
	Group Insurance	285,940	296,650
	Laundry & Uniform	3,522,126	3,392,501

		Amount in Taka	
		30-June-2019	30-June-2018
	Repair and Maintenance for house rent	691,990	697,134
	Repair & Upkeep	5,963,676	5,717,787
	Legal & License Fee	1,207,915	478,506
	Board Meeting Expenses	1,905,000	2,390,050
	Audit Fees	250,000	250,000
	Municipal Tax	651,603	639,303
	Staff Medicine	1,667,245	1,625,948
	AGM Expenses	54,195	445,938
	Credit Rating Fees	200,000	227,811
	Misc. Expenses	191,386	182,273
		<b>121,578,393</b>	<b>107,988,895</b>
<b>25.00</b>	<b>Non Operating Income</b>		
	Rental Income	8,078,400	5,766,000
	Interest (Globex Pharma)	1,200,000	900,000
	Bank Interest	3,913,675	8,905,827
		<b>13,192,075</b>	<b>15,571,827</b>
<b>26.00</b>	<b>Financial Expenses</b>		
	Interest expenses on long term loan	35,655,856	28,730,761
	Interest expenses	11,316,354	4,951,332
	Bank Charges	1,051,794	1,297,648
		<b>48,024,004</b>	<b>34,979,741</b>
<b>26.01</b>	<b>Total Interest Charged during the Year</b>		
	<b>Transferred To Capital Work In process- Building :</b>		
	BASIC Bank A/C # 694 (New Building 2nd Phase)	-	2,650,163
	BASIC Bank A/C # 829 (New Building 2nd Phase)	-	8,262,336
	BASIC Bank A/C # 876 (New Building 2nd Phase)	-	5,360,105
	BASIC Bank A/C # 881 (New Steel Building)	-	136,824
	NCCB-382(Basic-881)	-	258,726
	NCCB-391(Basic-829,876,694)	33,992,603	16,804,180
	NCCB-444	18,087,297	2,202,466
	NCC Bank Term Loan 102-233542-LInac-3	4,861,363	-
	NCC Bank Term Loan No.-102-233533-Medical Gas	642,418	-
	NCC Bank Term Loan No-102-233560-Building New	848,990	-
	<b>Total IDCIP</b>	<b>58,432,671</b>	<b>35,674,800</b>
	<b>Financial Expenses</b>		
	Interest Expenses on long Term Loan	35,655,856	28,730,761
	Interest Expenses - CC Loan	11,316,354	4,951,332
	Bank Charges	1,051,794	1,297,648
	<b>Total Financial Expenses</b>	<b>48,024,004</b>	<b>34,979,741</b>
	<b>Total</b>	<b>106,456,675</b>	<b>70,654,541</b>
<b>27.00</b>	<b>Basic Earnings Per Share (EPS) Disclosure Under IAS 33 "Earnings Per Share"</b>		
<b>27.01</b>	<b>Basic Earnings Per Share</b>		
	The Computation of EPS is given below:		
	Net profit for the year	69,904,158	68,999,833
	Weighted average number of Shares at June 30 ( Note-27.03)	33,212,694	33,212,694
	<b>Basic EPS</b>	<b>2.10</b>	<b>2.08</b>
<b>27.02</b>	<b>Diluted/Adjusted Earnings per Share</b>		
	Net profit after tax	69,904,158	68,999,833
	Total existing number of shares	33,212,694	33,212,694
	<b>Diluted/Adjusted Earning per Share</b>	<b>2.10</b>	<b>2.08</b>

		Amount in Taka	
		30-June-2019	30-June-2018
<b>27.03 Weighted average /Total existing number of shares</b>			
Opening number of shares outstanding [considered FV Tk.10 each]		33,212,694	33,212,694
		<b>33,212,694</b>	<b>33,212,694</b>
<b>27.04 Number of Outstanding shares</b>			
Opening number of shares outstanding [considered FV Tk.10 each]		33,212,694	33,212,694
		<b>33,212,694</b>	<b>33,212,694</b>
<b>28.00 NAV per Share</b>			
<b>28.01 NAV per Share with revaluation</b>			
Shareholders' Equity including revaluation surplus		1,522,595,928	1,491,935,170
Number of ordinary Shares Outstanding [Note-27.03]		33,212,694	33,212,694
Net Asset Value - NAV		<b>45.84</b>	<b>44.92</b>
<b>28.02 NAV per Share without revaluation</b>			
Shareholders' Equity without revaluation surplus		551,870,579	517,742,770
Number of ordinary Shares Outstanding [Note-27.03]		33,212,694	33,212,694
Net Asset Value - NAV		<b>16.62</b>	<b>15.59</b>
<b>29.00 Cash received from Customers and Others</b>			
Revenue [Note:22.00]		653,300,110	592,242,162
Accounts Receivable (Increases)/decreases		2,787,342	(1,579,464)
		<b>656,087,452</b>	<b>590,662,698</b>
<b>30.00 Cash Paid to Suppliers</b>			
Oxygen & Misc. Purchases		(27,917,056)	(25,728,519)
Cost of Medicine Sold		(153,243,885)	(140,529,677)
Pathology / X-Ray		(6,785,210)	(5,512,350)
Physiotherapy Expenses		(251,702)	(179,180)
Accounts Payable decreases		(2,900,952)	(470,250)
Changes in Inventory		(3,313,219)	(2,561,343)
		<b>(194,412,024)</b>	<b>(174,981,319)</b>
<b>31.00 Cash Paid to Employees &amp; Others</b>			
Direct Expenses		(129,330,285)	(105,525,366)
Administrative Expenses		(121,578,393)	(107,988,895)
Advances, Deposits & Prepayments		845,950	(1,604,571)
WPPF & Welfare Fund		(5,420,482)	(5,350,401)
Accrued expenses & Other Liabilities		4,762,820	1,701,340
Bank Charge		(1,051,794)	(1,297,648)
		<b>(251,772,183)</b>	<b>(220,065,542)</b>
<b>Tax Paid</b>			
Opening Balance		48,764,516	45,690,623
Add : Provision made during the year		10,184,004	26,693,151
		<b>58,948,520</b>	<b>72,383,774</b>
Less: Excess Provision Adjustment		9,692,416	-
		<b>49,256,104</b>	<b>72,383,774</b>
Less: Closing Balance		46,569,571	48,764,516
Tax Adjustment		<b>2,686,533</b>	<b>23,619,258</b>
Less : Advance Tax Adjustment		(12,378,949)	(23,619,258)
Advance Tax Paid		3,434,995	19,930,366
<b>Total Tax Paid</b>		<b>3,434,995</b>	<b>19,930,366</b>
<b>32.00 Dividend paid</b>			
Opening balance of unclaimed dividend		7,754,544	7,027,842
Add: Cash Dividend made during the year		39,855,233	39,855,233
		47,609,776	46,883,075
Less: Closing balance of unclaimed dividend		7,170,826	7,754,544
Dividend paid during the year		<b>40,438,951</b>	<b>39,128,531</b>



Amount in Taka	
30-June-2019	30-June-2018

**33.00 Reconciliation of Net operating cash flow under Indirect Method**

Clause No. 5 (2) ( e ) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018:

<b>Net Profit after Tax</b>	<b>69,904,158</b>	<b>68,999,833</b>
Depreciation	79,790,389	73,540,147
Rental Income	(8,078,400)	(5,766,000)
Intrest Expenses	46,972,210	33,682,093
WPPF & Welfare Fund-PL	4,741,489	5,420,482
Provision for Tax	24,925,614	39,409,800
Intrest Income	(5,113,675)	(9,805,827)
Accounts Receivable (Increases)/decreases	2,787,342	(1,579,464)
Accounts Payable Increases/(decreases)	(2,900,952)	(470,250)
Changes in Inventory (Increases)/decreases	(3,313,219)	(2,561,343)
Advances, Deposits & Prepayments (Increases)/decreases	845,950	(1,604,571)
WPPF & Welfare Fund Increases/(decreases)	(5,420,482)	(5,350,401)
Accrued expenses & Other Liabilities Increases/(decreases)	4,762,821	1,701,340
Tax paid	(3,434,995)	(19,930,366)
<b>Net Cash flow from Operating Activities</b>	<b>206,468,250</b>	<b>175,685,471</b>

### 34.00 Related Party Disclosures:

The details of related party transactions made during the year along with the relationship is illustrated below in accordance with IAS 24.

Particulars			Jul'18-June'19	Jul'17-June'18
Name of the Party	Relationship with Company	Nature of Transaction	Transacted /Balance Amount in BDT	Transacted /Balance Amount in BDT
Mr. Abu Saleh Abdul Muiz	Chairman & Shareholder	Remuneration	-	-
		Meeting Fee	180,000	150,000
Dr. Syed Mukarram Ali	Managing Director & Shareholder	Remuneration	5,900,000	5,900,000
		Meeting Fee	240,000	250,000
Directors & Shareholders		Meeting Fee	1,905,000	2,390,050
Delta Life Insurance Co. Ltd.	Common Shareholder	Group Insurance	285,940	296,650
Globex Pharmaceuticals Ltd.	Shareholder	Loan & Interest	14,210,475	13,010,475
Globex Pharmaceuticals Ltd.	Shareholder	Investment	34,316,517	34,316,517
Delta Medical College	Common Shareholder	Short Term Loan	7,579,861	-

### 35.00 Disclosure of Managerial Remuneration

35.01 The total amount of remuneration paid to the Managing Director of the company during the year is as follows :

Name	Designation	Jul'18-June'19	Jul'17-June'18
Dr. Syed Mukarram Ali	Managing Director	5,900,000	5,900,000

\* Noted that- Company provide full time car facilities to Managing Director.

35.02 Aggregate amount of remuneration paid to all Officers during the accounting year is as follows

Particulars	Nature of Payment	Jul'18-June'19	Jul'17-June'18
Directors	Board meeting fee	1,905,000	2,390,050
Officers & Executives	Salary, Bonus & Other allowances	190,308,139	156,563,365

### 36.00 Contingent Liabilities

36.01 Contingent liabilities of the company in respect of disputed additional VAT and penal VAT demanded by Customs Excise VAT authorities are as follows.

#### Particulars

Additional VAT

Penal VAT

Miscellaneous Claims

**Total**

#### Amount In Tk.

1,089,747

1,089,747

435,898

**2,615,392**

In the Hon'ble Supreme Court of Bangladesh High Court Division appeal No- 10 of 2006 is pending on the imposition of additional VAT and penalty thereof on the company by the Customs Excise and VAT Appellate Tribunal. The decision from the Hon'ble High Court in this regard is pending .The required provision if any, arises out of the court case will be made in the year of disposal of the case.

36.02 Assessment of the Income Tax up to the Assessment year 2017-2018 has been completed. Assessment of the Income Tax for the Assessment year 2018-2019 is under process. Therefore, adjustment of the income tax for the Assessment year 2018-2019 did not made in the financial statements during the year 2019.

### 37.00 General :

a) **Audit Fee :** Audit fee of Tk.250,000 represents only the audit fee Inclusive of VAT & TAX.

b) The 635 number of employees have been engaged in the company. The lowest individual employees are paid total remuneration of BDT 72,000 in a year and above.

**DELTA HOSPITAL LIMITED**  
**Annexure of Property, Plant & Equipment**  
As at June 30, 2019

Annexure-A

Particulars	Cost			Rate of Dep	Depreciation			W.D.V as at 30.06.19
	Balance as at 01.07.18	Addition during the year	Adjustment during the year		Balance as at 01.07.18	Addition during the year	Adjustment during the year	
Land	16,733,087	-	-	0%	-	-	-	16,733,087
Land development	696,129	-	-	0%	-	-	-	696,129
Building & Construction	539,777,863	220,116,000	-	5.5%	38,227,432	27,585,274	-	694,081,157
Wasa, Gas line installation/Deep	1,620,594	-	-	20%	952,332	133,652,38	-	534,610
Furniture & fixture	20,334,580	1,257,318	-	15%	9,313,726	1,747,427	-	10,530,745
Electricity & sanitary fittings	2,844,513	-	-	20%	2,043,344	160,233,78	-	640,935
Machinery & equipment	752,687,129	30,305,602	-	10%	334,547,115	43,329,282	-	405,116,335
Surgical equipment	3,050,198	-	-	12%	1,486,430	187,652,20	-	1,376,116
Electrical equipment	7,523,935	60,000	-	15%	3,976,256	536,652	-	3,071,027
Office equipment	5,599,111	-	-	20%	3,568,315	406,159,26	-	1,624,637
Motor vehicles	17,056,545	-	-	15%	6,222,054	1,625,174	-	9,209,317
<b>Sub-Total as at June 30, 2019</b>	<b>1,367,923,684</b>	<b>251,738,920</b>	<b>-</b>		<b>400,337,002</b>	<b>75,711,505</b>	<b>-</b>	<b>1,143,614,097</b>
<b>Sub-Total as at June 30, 2018</b>	<b>1,164,196,394</b>	<b>203,727,290</b>	<b>-</b>		<b>331,149,437</b>	<b>69,187,565</b>	<b>-</b>	<b>967,586,682</b>

Revaluation:

Particulars	R E V A L U A T I O N			Rate of Dep	Depreciation			W.D.V as on 30.06.19
	Balance as on 01.07.18	Addition during the year	Adjustment during the year		Balance as on 01.07.18	Addition during the year	Adjustment during the year	
Land	952,982,983	-	-	0%	-	-	-	952,982,983
Building	92,285,163	-	-	5.5%	26,451,518	3,620,850	-	62,212,795
Machinery & Equipment	6,016,826	-	-	10%	3,282,888	273,394	-	2,460,544
Motor vehicles	3,394,406	-	-	15%	2,163,477	184,639	-	1,046,289
<b>Sub-Total as at June 30, 2019</b>	<b>1,054,679,378</b>	<b>-</b>	<b>-</b>		<b>31,897,883</b>	<b>4,078,884</b>	<b>-</b>	<b>1,018,702,610</b>
<b>Sub-Total as at June 30, 2018</b>	<b>1,054,679,378</b>	<b>-</b>	<b>-</b>		<b>27,545,301</b>	<b>4,352,581</b>	<b>-</b>	<b>1,022,781,495</b>

Total as on June 30, 2019

Total as on June 30, 2018

2,422,603,062	251,738,920	-	2,674,341,982	-	432,234,885	79,790,389	-	512,025,275	2,162,316,707
2,218,875,772	203,727,290	-	2,422,603,062	-	358,694,739	73,540,147	-	432,234,886	1,990,368,177

# Delta Hospital Limited

26/2, Principal Abul Kashem Road, Mirpur-1, Dhaka-1216  
Phone: 9029152, 58053461, 58050661, 58050663, 9022410, Mob: 01720238662, Fax: 880-2-9011372  
E-mail: delta@delta-hospital.com, Web site: www.delta-hospital.com

## PROXY FORM

I/We .....  
of.....  
being a member of Delta Hospital Limited do hereby appoint  
Mr./Mrs./Miss.....  
Of .....or (failing his/her)  
Mr./Mrs./Miss.....  
of.....  
as my/our proxy to vote for me/us and on my/our behalf at the 33<sup>rd</sup> Annual General Meeting of the Company to be held on Friday, 20<sup>th</sup> March, 2020 at 3.30 p.m. at Delta Hospital's Auditorium (9<sup>th</sup> Floor, Block-B), 26/2, Principal Abul Kashem Road, Mirpur-1, Dhaka-1216 and any adjournment thereof or at any ballot to be taken in consequence thereof.  
Signed this.....day of.....  
Signature of Proxy.....Signature of Shareholder.....  
Folio No.....

Revenue  
Stamp  
Tk. 20/-

### Note:

- 1) This form of proxy, duly completed, must be deposited at least 48 hours before the meeting at the company registered office. Proxy is invalid if not signed and stamped as explained above.
- 2) Signature of the Shareholders should agree with the Specimen signature registered with the company.

# Delta Hospital Limited

26/2, Principal Abul Kashem Road, Mirpur-1, Dhaka-1216  
Phone: 9029152, 58053461, 58050661, 58050663, 9022410, Mob: 01720238662, Fax: 880-2-9011372  
E-mail: delta@delta-hospital.com, Web site: www.delta-hospital.com

## ATTENDANCE SLIP

I hereby record my attendance at the 33<sup>rd</sup> Annual General Meeting of the Company to be held on Friday, 20<sup>th</sup> March, 2020 at 3.30 p.m. at Delta Hospital's Auditorium (9<sup>th</sup> Floor, Block-B), 26/2, Principal Abul Kashem Road, Mirpur-1, Dhaka-1216.

Name of Member/Proxy.....

Folio no.....

Signature .....Date.....

### Note:

Shareholders' attending meeting in person or by proxy is requested to complete the attendance slip and hand it over the entrance of the meeting hall.

রেডিওথেরাপী প্রযুক্তিতে নতুন সংযোজন

## LINEAR ACCELERATOR (TrueBeam) এখন ডেল্টা হাসপাতালে

এই মেশিনের মাধ্যমে শরীরের যে কোন জায়গার ক্যান্সার যেমন- ফুসফুসের ক্যান্সার, ব্রেস্ট ক্যান্সার, প্রোস্টেট ক্যান্সার, নাক.কান.গলার ক্যান্সারসহ অন্যান্য ক্যান্সারে উন্নতমানের রেডিয়েশন থেরাপি দেয়া হয়।



২৪ ঘন্টা জরুরী বিভাগ	২৪ ঘন্টা ফার্মেসী সেবা	২৪ ঘন্টা ব্লাড ব্যাংক সার্ভিস
ছুটির দিন ব্যতিত প্রতিদিন সকাল ৮টা হইতে দুপুর ২টা পর্যন্ত সকল বিভাগের বহির্বিভাগ খোলা থাকে।	আউটডোরে স্বল্প খরচে বিশেষজ্ঞ চিকিৎসকগণ দ্বারা চিকিৎসা দেয়া হয়।	
মুমূর্ষ রোগীদের জন্য ICU ও HDU সুবিধা	প্যালিয়েটিভ কেয়ার ইউনিট Palliative Care Unit	
নবজাতকের বিভিন্ন সমস্যার জন্য NICU (এন.আই.সি.ইউ) সুবিধা	আধুনিক প্রযুক্তিতে ব্যথামুক্ত নরমাল ডেলিভারী করানো হয়।	
ফিজিওথেরাপী ইউনিট (Physiotherapy Unit)		
ক্যান্সার চিকিৎসা সমূহ		
রেডিওথেরাপী	কেমোথেরাপী	
ব্র্যাকিথেরাপী	ক্যান্সার সার্জারী	

আধুনিক বিশ্বে রেডিওথেরাপীতে ব্যবহৃত উন্নত প্রযুক্তি সম্পন্ন যন্ত্রপাতি; তিনটি 3D CRT & IMRT DIGITAL লিনিয়ার এক্সিলারেটর, দুইটি কোবাল্ট-৬০, যার সাহায্যে রেডিওথেরাপী দেয়া হয়। রেডিওথেরাপী প্লানিং এর জন্য রয়েছে দুইটি অত্যাধুনিক সিমুলেটর। ব্র্যাকিথেরাপীর জন্য রয়েছে HDR ব্র্যাকিথেরাপী এবং রোগ নির্ণয়ের জন্য রয়েছে অত্যাধুনিক প্যাথলজিক্যাল ল্যাব।

### ❖ অন্যান্য চিকিৎসা বিভাগ :

- |                       |                         |                        |                 |
|-----------------------|-------------------------|------------------------|-----------------|
| ➤ মেডিসিন             | ➤ শিশু ও নবজাতক         | ➤ চর্ম ও যৌন রোগ       | ➤ কার্ডিওলজি    |
| ➤ সার্জারী            | ➤ ই এন টি (নাক কান গলা) | ➤ হেমাটোলজি (রক্তরোগ)  | ➤ দন্ত          |
| ➤ সার্জিক্যাল অনকোলজি | ➤ অর্থোপেডিক্স          | ➤ গ্যাস্ট্রোএন্টেরোলজি | ➤ এনাসেসথেসিয়া |
| ➤ গাইনী এন্ড অবস      | ➤ চক্ষু                 | ➤ মানসিক রোগ           | ➤ ফিজিওথেরাপী   |

### ❖ ডায়াগনস্টিক সুবিধা :

- |   |   |   |   |
|---|---|---|---|
| <input type="checkbox"/> ক্লিনিক্যাল প্যাথলজি | <input type="checkbox"/> ভাইরোলজি                           | <input type="checkbox"/> হরমোন                      | <input type="checkbox"/> ইসিজি            |
| <input type="checkbox"/> হেমাটোলজি            | <input type="checkbox"/> সেরোলজি                            | <input type="checkbox"/> ব্লাড ট্রান্সফিউশন সার্ভিস | <input type="checkbox"/> ইকো কার্ডিওগ্রাম |
| <input type="checkbox"/> বায়োকেমিস্ট্রি      | <input type="checkbox"/> এফ এন এ সি                         | <input type="checkbox"/> ER                         | <input type="checkbox"/> আলট্রাসোনোগ্রাম  |
| <input type="checkbox"/> মাইক্রোবায়োলজি      | <input type="checkbox"/> হিসটোপ্যাথলজি                      | <input type="checkbox"/> PR                         | <input type="checkbox"/> এন্ডোস্কোপি      |
| <input type="checkbox"/> সাইটোলজি             | <input type="checkbox"/> টিউমার সনাক্তকরণ (মার্কার ষ্টাডিজ) | <input type="checkbox"/> HER-2                      | <input type="checkbox"/> সিটি স্ক্যান     |
| <input type="checkbox"/> ইমিউনোলজি            | <input type="checkbox"/> ক্রোমোজম                           | <input type="checkbox"/> এক্স-রে                    | <input type="checkbox"/> মেমোগ্রাম        |

### ❖ ফ্লোজেন সেকশন :

বাংলাদেশে বেসরকারী খাতে ডেল্টা হাসপাতাল লিঃ প্রথম প্রতিষ্ঠান যেখানে অস্ত্রোপচারের সময় রোগীর প্যাথলজি পরীক্ষা করে কয়েক মিনিটের মধ্যে ক্যান্সার ও অন্যান্য রোগ নির্ণয় করা হয়।



## ডেল্টা হাসপাতাল লিমিটেড Delta Hospital Limited

২৬/২, প্রিন্সিপাল আবুল কাশেম (সাবেক দারুস সালাম) রোড, মিরপুর-১, ঢাকা-১২১৬, বাংলাদেশ  
ফোন: ৯০২৯১৫২, ৫৮০৫০৬৬১, ৫৮০৫০৬৬৩, ৫৮০৫৩৪৬১, ৯০২২৪১০, মোবাইল: ০১৭২০২৩৮৬৬২  
E-mail: delta@delta-hospital.com, deltahospital1987@gamil.com, Web: www.delta-hospital.com  
উত্তরা ইউনিট : প্লট নং-২১, সেক্টর-০৮, আবদুল্লাহপুর, উত্তরা, ঢাকা-১২৩০, ফোন: ০১৭৮৭৬৬১৩৭৬